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Introduction:  The Human Immuno-deficiency Virus (HIV) and the consequent Acquired 
Immuno-Deficiency Syndrome (AIDS) have cost the lives of millions of people globally over 
the past 30 years since the first cases of illness appeared.  Due to the overlap in areas in the 
brain that are damaged by the HIV with those that control saccadic eye movements, screening 
of eye movement functions in children with HIV/AIDS could thus be a valuable early 
indicator of a declining neurological and immunological state.  Therefore,  movement testing 
through non-invasive means may give the optometrist valuable insight into the developing 
central nervous system (CNS) in HIV-infected children.   
Aim: To determine if abnormal saccadic eye movements in children with HIV/AIDS on 
HAART could be a predictor of the status of their immune system.   
Methodology:  The study population comprised of 128 conveniently selected subjects aged 5 
to 14years diagnosed with HIV/AIDS on HAART.  This prospective study, used a descriptive 
design.  The two significant biological parameters such as CD4 count and viral load (VL) data 
of patients were accessed and subjects performed the DEM test, which is a visual-verbal 
reading speed test, used to detect oculomotor function as well as automaticity skills.  The 
subjects were then classified according to the different „behaviour types‟ as is specified in the 
DEM test based on their test performances.  Statistical Analysis Software (SAS) version 9.2 
was used to analyse the data. 
 Results: Nine year olds were the most prevalent comprising of 23% of the sample.  Subjects 
were categorised into three categories of their VL and CD4 count parameters from minimal to 
severe immunosuppression.  Seventy eight percent (78%) of subjects had minimal 
immunosuppression with CD4 counts ≥500cells/mm
3
 with a median value of 778.5 cells/mm
3
.  
Sixty five percent (65%) of the subjects had undetectable VL (<40 copies/mm
3
) with the 
median value of <40 copies/mm
3
 in the sample.  With the DEM test, 93% had vertical and 
92% had horizontal times that were outside of the standardised DEM norm.  The classification 
of subjects into behaviour types revealed that 53% were type 3 – automaticity problems, 22% 
type 4 – oculomotor problems and automaticity problems, 8% type 1 – normal performance 









behaviour type category.  The relationship between the VL with behaviour types (p=0.2) and 
the CD4 count against the behaviour types (p=0.17) were neither statistically nor clinically 
significant, hence no relationship could be established.   
Discussion: Since the cognitive functioning in children with HIV/AIDS was moderately 
affected, the DEM test could be a valuable tool, if not to only detect eye movement problems 
but to assess the automaticity skills, which shows the impact on their neurodevelopment.  It 
therefore does prove to be worthwhile for optometrists and other health professionals to use 
the DEM test as part of a battery of neurodevelopmental tests to assess different 
neurocognitive functions, specifically in children with HIV/AIDS.    
Recommendation:  DEM norms for a South African paediatric population should be 
established as the characteristics of this population differ from the population of English-
speaking American children on which this test was standardised.  
Conclusion: Immunologic and virologic statuses in children with HIV/AIDS on HAART 
cannot be predicted from abnormal saccadic eye movements.  Performances across all age 
groups were significantly below the standard DEM norms. Saccadic eye movement 
abnormalities were the least prevalent and automaticity deficiencies were the most prevalent 
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Medical science is continuously searching for quicker, pragmatic, less invasive, 
and preferably cost-effective modes of investigation to study human behaviour and 
disease processes.  This is done in pursuit of finding quicker answers with a focussed 
goal of promoting longevity.  Modern medicine has widely accepted the concept that 
the sooner a disease or disorder is diagnosed, the sooner treatment interventions could 
be implemented.  This would result in better outcomes to sustain and prolong healthier 
living with minimal compromise.  This paradigm is a key concept in the approach to 
dealing with the burden of the Human Immunodeficiency Virus (HIV) and Acquired 
Immuno-Deficiency Syndrome (AIDS) worldwide.  
 
Clinicians are often challenged when investigating the central nervous system 
(CNS) to assess for defects without having to expose the patient to continuous and 
regular radiological investigations.  Some of these investigative techniques are 
invasive, costly and unfeasible in resource-limited settings and may sometimes not be 
conclusive of abnormalities in the very early stages of disease.  Eye movement testing, 
as a means to investigate CNS function, may not satisfy all of the desirable factors that 
medical science wants to achieve to study human behaviour and pathophysiology.  
However, for the past three decades, eye movement testing has been used more 
frequently as an experimental tool to gain insight into HIV and AIDS-related diseases, 









neurological disease (Leigh and Kennard, 2004; Kumra et al., 2001; Rayner, 1998; 
Amador et al., 1995; Currie et al., 1988; Hoffman and Rouse, 1980).  
 
The motive for placing value in studying eye movements in different diseases 
are for the very simple reason that eye movement control centres are located in the 
brain, providing us with a window to the CNS.  Eye movement testing is intrusive yet 
non-invasive.  It has been said that activity related to eye movements can be found in 
every corner of the brain (Leigh and Kanna, 2006; Leigh and Zee 2006).  The study of 
eye movements has been a useful source of information to clinicians and scientists 
where functional impairments can be a clue in localization of disease processes and the 
monitoring of existing disorders or diseases (Leigh and Zee 2006).  Leigh and Kanna 
(2006) further stated that eye movements are being used as an experimental tool in 
neuropsychological studies of memory and cognition. 
 
With the introduction of Highly Active Anti-Retroviral Therapy (HAART) in 
1996 (The CASCADE Collaboration, 2000), HIV has become as manageable as a 
chronic disease to those who have access to medication (Palella et al, 1998).  The 
overarching goals of antiretroviral therapy are to reduce HIV-related morbidity, 
improve quality of life and prolong survival of infected individuals.   The main drivers 
of the pandemic in South Africa are sexual transmission in adults and by mother-to-
child-transmission (MTCT) via breast milk in children (Baylor College of Medicine 










An inability to detect the virus in the blood while on HAART does not indicate 
clearance or absence of the virus from the body but that it is in a very low 
concentration, below the assay/sample threshold for that specific instrument used for 
analysis.  It may be found in other parts of the body, especially the CNS where it is in 
higher concentrations because of the variable blood-brain penetrative abilities of anti-
retroviral drug therapy (Kolson, Lavi and Gonzalez-Scarano, 1998).  
 
During the primary stage of infection of the human body by the HIV, the virus 
rapidly progresses to the central nervous system where it remains in a viral reservoir as 
found in cerebrospinal fluid (CSF) studies (Pilcher et al, 2001; De Luca et al, 2002).  A 
consequence of this neuro-invasion is the development of abnormal neurological and 
neurocognitive manifestations (Brouwers, Walters and Civitello 1998, pp.293-308) 
broadly termed HIV encephalopathy (Pilcher et al, 2001) with manifested eye 
movement abnormalities as one of the later signs.  HAART has resulted in the lower 
incidence of HIV-related encephalopathy (Tardieu, 2000), however children still 
exhibit neurocognitive decline in the presence of HAART. This reinforces the need for 
the development of screening and diagnostic tools to assess the neurocognitive and 
CNS functioning in HIV-infected children while the challenge to develop effective 
CNS-penetrating antiretrovirals continues. 
 
Special attention must be paid to the early detection of neurologic problems in 
children since their CNS is not completely developed and therefore vulnerable to 









problems in children often leads to favourable outcomes (BIPAI 2010, pp. 194-205).  
Infected children develop neurological dysfunction more frequently from HIV 
encephalopathy whereas infected adults develop neurologic dysfunction more 
frequently through opportunistic infections as the CNS as they harbour latent 
pathogens which produce disease when HIV-related immunologic depression occurs 
(Civitello 2005, pp.431-44). 
 
What remains vague and insufficiently researched is the pathogenic process of 
HIV progression through the developing CNS of children. It is also still unknown at 
which point a neurologic impairment occurs, that is observable and measurable 
through non-invasive techniques, while on HAART.  In addition, a consistent 
predictive marker of early and progressive neurologic impairment is yet to be 
established in this HAART era.  
  
Saccadic-type of eye movements are rapid eye movements that occur to align 
the visual axes of both eye with objects of interest where the eyes make a conjugate 
movement to jump from one object to the next (Johnson and Everling, 2008).   
Typically, about  three saccadic eye movements are made every second in everyday 
life without even being aware of it (Rayner, 1998) making it the most common type of 
eye movement action that we voluntarily and involuntarily use in everyday life.  
Saccades are used to scan our visual world as a way of gathering information through 
visual search (Leigh and Zee 2006, pp. 3-19).  The first use of the word saccade to 









scientist, Javal in 1879 (as cited by Caldara and Miellet, 2011) and has continued to be 
used and researched today over a century onwards, as an authentic tool to explore an 
array of diseases and paradigms in the neurosciences (Leigh and Kennard, 2004). 
 
Screening for ocular motility abnormalities by assessing saccadic eye 
movements forms part of a basic optometric examination (Scheiman et al, 2002).  
Assessments are done by gross observation through subjectively-induced motility tasks 
with rating scales to grade the eye movements (Maples, Atchley and Ficklin, 1992).  In 
a clinical setting, an alternative to the routinely employed gross observation methods of 
saccadic testing is the use of psychometric tests.  The Developmental Eye Movement 
test (DEM) is a simple psychometric test that is recommended as an appropriate 
oculomotor assessment tool in optometric clinical practice for school-aged children 
(Garzia et al, 1990; Tassinari and Deland, 2005). 
 
Manifestation of saccadic irregularities in HIV positive children in an 
optometric examination may indicate HIV-related neurologic complications and 
subsequently lead to early referral for further investigation and intervention.  The DEM 
test could be used as a non-invasive screening tool to monitor CNS disease progression 
as it is established that the architecture and control centre of eye movements is located 
in the brain.  This approach is analogous to the use of fundus photography as a 
screening and monitoring tool in patients with diabetic retinopathy (Williams et al, 
2004).  Alternatively, the CD4 count and viral load may be able to predict if a child 










Neurological preservation is one of the key outcomes of antiretroviral therapy 
therefore ocular motor testing and its performance rates could be used along with other 
cognitive, perceptual and functional tests, as a non-invasive CNS-probing aid in 
children to monitor treatment efficacy in achieving and sustaining neurological 
preservation.  These DEM test scores in children could be an adjunct investigation to 
neuropsychological testing and other concomitant investigations as part of a battery of 
tests to examine a single parameter of neurologic functioning.  The results may be 
consolidated to provide prognostic evidence to implement the appropriate interventions 
to achieve a better clinical outcome. 
 
By investigating saccadic eye movements in HIV positive children, the 
researcher sought to find out if saccadic eye movement disorders can be a marker for a 
declining neurological and neuropsychological state in HIV infected children on 
HAART.  Secondly, the researcher intended to explore if manifestations of these 
ocular motility abnormalities correlate well with the progressive nature of the disease 
by evaluating its association to biomarkers such as CD4 count and viral load in the 
presence of HAART.   
 
Paediatric research in neurocognitive and neurodevelopmental anomalies in 
HIV/AIDS remains scarce as there are currently no published studies on saccadic eye 
movement abnormalities in HIV positive children in South Africa and Sub-Saharan 









contributing to the body of knowledge on the role of child-based saccadic eye 
movement testing in HIV/AIDS for health professionals and health scientists.  Insight 
into this is crucial in the overall interest of longevity and neurological preservation 
with healthy cognitive development and maturation of an infected child. 
 
HIVAIDS remains a major concern to all South Africans as this epidemic not 
only significantly affects the South African health infrastructure by straining human 
and medical resources, but also has resulted in a plunge in the life expectancy of the 
South African population (Mba, 2007).  It further carries a heavy social and economic 
burden to South Africa.  As health professionals and researchers, we need to find ways, 
within our own scopes of practice, to support and contribute towards universal health 
care to confront the challenges of HIV/AIDS that face South Africa.  
 
Saccadic eye movement screening has contributed significantly in other areas 
of human biology in the understanding of disease processes.  For this reason, it is thus 
prudent to investigate the value and reliability of this tool in contributing knowledge in 

















This chapter is divided into two sections.  The first section provides a foundational 
framework that defines the disease, an overview of its epidemiology with global and 
local perspectives on health care strategies and implementation.  The second section 
provides a focused review on the various published scholarship related to this study, 
namely, saccadic eye movement testing, tools of CNS investigation in CNS disorders 
and their application in HIV/AIDS and universal health care. 
 
2.1 THEORETICAL FRAMEWORK 
 
2.1.1 HIV/AIDS: Global and National Epidemiological Outlook 
 
 
In 1981, in the United States of America (USA) and elsewhere, a new disease, 
an unnamed syndrome appeared in a few homosexual men and was primarily 
characterised by a deficiency in the immune system. The virus called HIV was first 
cultured in 1983 and subsequently identified in 1984 as the causative viral agent that 
weakens the immune system (Barré-Sinoussi et. al, 1983; Popovic et al, 1984) and the 
cause of the disease called AIDS (Barré-Sinoussi, 1996; Singh, Bairy and Shivananda, 
2003).  Early observations showed that the common modes of transmission of HIV 
were spread through intimate sexual contact e.g. genital fluids, blood and MTCT 









According to the World Health Organisation (WHO) for the purposes of HIV 
case definitions for reporting and surveillance, a child is defined as less than 15 years 
of age and an adult as 15 years and over (WHO, 2007).  Current global figures of the 
HIV epidemic estimates are that there are 34.2 million [31.8 – 35.9] people living with 
HIV in the world today of which 3.4 million [3.0 – 3.8] are children (UNAIDS, 
2012b).  It is estimated that 90% of all HIV positive children live in Sub-Saharan 
Africa where the global burden of HIV remains the greatest (WHO, UNAIDS and 
UNICEF, 2010; UNAIDS, 2010).  In 2010, 1.8 million people died globally through 
AID-related illness of which 250 000 were children (WHO, UNAIDS and UNICEF, 
2010).  There are 8 million people that have access to antiretroviral treatment in middle 
to low economic countries with 562 000 of those being children (UNAIDS, 2012a).  
The WHO declared that the lack of sufficient access to HIV treatment is a global health 
emergency and called for urgent strides across all nations to ensure increased global 
access to treatment (WHO, 2004).  There is an international drive to reach 15 million 
people by 2015 with antiretroviral therapy as set out by the 2011 Political Declaration 
on HIV and AIDS with unanimous support from the United Nations‟ member states 
(UNAIDS, 2012a). 
Since the first recorded case of HIV/AIDS in South Africa in 1982 (Karim and 
Karim, 2002), the same year the term „AIDS‟ was coined, it has reached pandemic 
levels on its 30
th
 anniversary with 5.38 million South Africans infected (Statistics SA, 
2012a).  A 2010 report by the WHO placed the number of people living with HIV and 
AIDS in South Africa at 5.6 million [5.4 – 5.9] (WHO, UNAIDS and UNICEF, 2010, 









(Statistics SA, 2012a) with the highest recorded absolute number of  HIV positive 
adults and children in the world, which exceeds the number of infected people in all of 
Asia.  There was an estimated number of 377 000 children between the ages of 0 and 
14 that are in need of HAART with an estimated number of 105 000 children in the 
same age category that were receiving it in 2011 (Statistics SA, 2012a).  The UNAIDS 
recorded 29 100 new HIV infections in children under 15 years of age in 2011 in South 
Africa (UNAIDS, 2012a). 
In the Free State province, there were 345 000 people living with HIV in 2009 
(UNAIDS, 2012b).  As of June 2011, there were 152 ARV treatment facilities in the 
province with the number of children registered on HAART being 9643.  Due to 
attrition for a number of reasons, the actual number was reduced to 8020 (Republic of 
South Africa (RSA). Free State Department of Health, 2011).  Although these figures 
do paint a bleak picture on the global outlook, the tide is turning with a steady decline 
in AIDS-related deaths due to HAART as well as a decline in the incidence of new 
HIV infections in South Africa and abroad (WHO, UNAIDS and UNICEF, 2010; 
UNAIDS 2012a, 2012b).  Global figures of children living with HIV seem to be 
levelling off as well (WHO, UNAIDS and UNICEF, 2010).  Even though South Africa 
has made significant gains in addressing the HIV/AIDS epidemic over the past 10 
years, there unfortunately still remains a significant gap in treatment distribution 
between the number of adults versus the number of children, globally and locally 










 This three-decade long epidemic has claimed millions of lives and will continue 
to claim many more but a hope for a cure is insight as reported in an article by 2008 
Nobel Laureate of Medicine, French researcher Francoise Barré-Sinoussi, who was 
part of a team that discovered HIV (SAPA-AFP, 2012).  She further shared some 
optimism by citing a case of a patient that was cured of HIV in Berlin after having a 
bone marrow transplant in 2009 (SAPA-AFP, 2012).  There has been documented 
cases of less than 5 people in the world that have been cured from HIV.  
 
2.1.2  Testing, Diagnosis and the Classification System of HIV/AIDS in Children, 
globally and in South Africa. 
 
Diagnosis of HIV infection in children born to HIV-infected mothers is not as 
simple when compared to that in adults.  The complication exists by the presence of 
maternal anti-HIV IgG antibodies in the blood of the new borns due to trans-placental 
transmission to the fetus (Center for Disease Control and Prevention (CDC), 1994).  
These maternal antibodies usually remain in a child up to 18 months of age so HIV 
antibody testing within this window period would be unreliable in confirming the 
diagnosis of HIV infection (Simpson and Andiman, 1994).  Children born to HIV 
infected mothers are classified as „HIV exposed‟ prior to the confirmation of HIV 
status.  It is only after this period of 18 months that the status can be changed to a 
„seroreverter‟ or HIV negative if enzyme immunoassay (EIA) testing reveals absence 
of HIV antibodies (CDC, 1994).  Polymerase Chain Reaction (PCR) and virus culture 









children born to infected mothers prior to 18 months of age as these tests directly 
investigate the presence of viral genetic material in the blood of new borns (CDC, 
1994; BIPAI 2010, pp. 7-14).  
 
Initially in 1990, the WHO developed a four-stage clinical HIV/AIDS staging 
system for adults.  The WHO thereafter developed a pre-HAART classification system 
for infants and children for clinical staging and immunological profiling of HIV 
infection and related disease.  This revised four-stage system that was originally 
intended for surveillance and case reporting (WHO, 2007; BIPAI 2010, pp.15-44; 
RSA, Kwa-Zulu Natal Department of Health (KZN DOH), 2010; USA, Department of 
Health and Human Services (DHHS), 2011) was then developed for other purposes.  
This updated system was intended to assist in clinical management of HIV, 
determination of prognosis, strengthening of the clinical diagnosis,  guidance in 
decisions regarding treatment initiation and to facilitate the scaling up of access to 
antiretroviral therapy (WHO, 2007).  The WHO classification system closely relates to 
the system used CDC, which has classified HIV infection in children into three 
domains which were, Infectious Status, Immunologic Status and Clinical Status that 
which are still used today (CDC, 1994).  
 
A CD4 cell count is a direct indicator of how healthy the immune system is and 
is expressed as cells per microlitre (µL) or cubic millimeters (mm
3
) (USA, DHHS, 
2011; AIDSINFO, 2011).  In children, the CD4 absolute count is expressed as a 









absolute value as is expressed with adults.  Among children younger than 5 years of 
age, the absolute CD4 count tends to fluctuate more than the CD4 percentage as 
compared to children older than 5 years of age.  It is for this reason that the 
measurement of the CD4 percentage was thought to be more reliable in younger 
children 5 years old or less (Raszka et al, 1994).  This is due to the variability in the 
absolute value measurement which could be influenced by a series of physiological 
factors and concurrent illnesses (Raszka et al, 1994; WHO, 2007).  However, the 
availability of laboratory equipment to produce the CD4 percentage in resource-limited 
settings is not always available whereas equipment to determine the absolute CD4 
value is more readily available (WHO, 2007).  The absolute CD4 cell count and CD4 
percentage in uninfected infants are considerably higher than those observed in 
uninfected adults (WHO, 2007).  The CD4 count then stabilises to adult levels by 6 
years of age.  Age must therefore be taken into account as a variable in considering 
absolute CD4 counts and CD4 percentages (Bunders, Cortina-Borja and Newell, 2005; 
Ochieng et al, 2006; Shah, 2006).  
 
The HIV viral load (VL) is the best indicator of how active the virus is in the 
body.  Viral load testing is a useful predictor of clinical disease progression 
(Marschner et al, 1998; Thiebaut et al, 2000).  The higher the viral load in the blood 
plasma, the lower would the CD4 count be as the virus destroys the CD4 lymphocyte 
cells (Yeni et al, 2002).  Viral load testing directly tests the quantity of viral genetic 









replication as copies/ml (Rogers et al, 1989; Krivine et al, 1992; Food and Drug 
Administration (FDA), 2007).  
 
In the South African public health sector, the Free State Department of Health 
utilizes the services of the National Health Laboratory Services (NHLS) with a 
regional branch located at Pelonomi Regional Hospital in Bloemfontein for the CD4 
and viral load analysis as well as other HIV-related pathology analyses.  The reference 
interval used by the NHLS for a normal CD4 count is 500 – 2010 cells/ µL.  In both 
HIV-infected children and adults, HIV viral load, CD4 absolute count and percentage 
are independent predictors of disease progression and mortality risk but with the 
combined use of these two biomarkers, prognosis of infected individuals can be more 
accurately determined (Mellors et al, 1996; Mofenson, et al, 1997; Palumbo et al, 
1998). 
 
2.1.3  South African ART Programme and Policy Implementation Guidelines 
 
The South African ART programme, known as the Comprehensive Care 
Management, Treatment and Support (CCMTS) programme was launched in 2003 
(RSA. National Department of Health (NDOH)/ South African National AIDS Council 
(SANAC), 2010a).  Although the programme achieved much success, ongoing high 
mortality from HIV/AIDS indicated that substantial changes were required in order to 
improve access to HIV care and the overall success of the programme (RSA. 









larger number of ART facilities which stood at 2 552 facilities in South Africa (RSA. 
NDOH/SANAC, 2012).  A new treatment guideline was recommended and is in the 
implementation phase in South Africa.  The proposal for an improved treatment 
protocol came from supported knowledge that HAART reduces the HIV-related 
morbidity and mortality if treatment was initiated earlier than was currently practiced 
subsequently improving the quality of life over an extended period (Palella et al, 1998).  
These recommendations would however mean a substantial increase in the number of 
patients who will require both treatment and early HIV testing (Lodi et al, 2011). 
 
The progress update was officially announced on the 1
st
 of December 2009 at 
the World Aids Day, by the Honourable President Jacob Zuma for new interventions 
for improving antiretroviral access in order to decrease the disease burden, to address 
maternal and child mortality and to improve life expectancy (RSA. NDOH/SANAC, 
2010a; 2010b).  The specific objectives of the new HAART programme in South 
Africa are to prioritize ARVs for patients with CD4 counts < 200 cells/mm
3
 or with 
severe HIV-related opportunistic disease irrespective of CD4 count, patients co-
infected with HIV and tuberculosis (TB) with CD4 < 350 cells/mm
3
 and pregnant 
women with CD4 < 350 cells/mm
3
 for lifelong ART and CD4 > 350 cells/mm
3
 for 
prophylaxis (RSA. NDOH/SANAC, 2010a).  One of the most sought after 
improvements recommended was to initiate therapy for all infected infants less than 











2.1.4  Highly Active Anti-Retroviral Therapy (HAART) in HIV-Infected Children 
 
 
The specific objectives of antiretroviral therapy are to target maximal 
suppression of viral load in the body and to preserve immunologic functions (USA. 
DHHS, 2013).  Since the development and commercial use of Zidovudine (AZT) as 
mono-therapy in 1987, significant advances had been made in antiretroviral therapy 
with the introduction of HAART in 1996 (The CASCADE Collaboration, 2000; 
AIDSINFO, 2011).  Currently, there are six drug classes of anti-retrovirals in existence 
with 24 different agents licensed for use, each with their own dosage forms and dose 
concentrations (Tang and Shafer, 2012).  Each class of drugs are unique in their 
mechanism of action that interrupts at different stages, the life cycle of the virus 
(Rathbun, 2011; Tang and Shafer, 2012).  It is a standardized international 
recommendation that the drug regimen for HAART initiation be comprised of a 3 drug 
regimen with 2 agents from the nucleoside reverse transcriptase inhibitor (NRTI) class 
and 1 agent from either the non-nulceoside reverse transcriptase inhibitor (NNRTI),  
protease inhibitor (PI) or the integrase inhibitor (II) classes (WHO, 2004; WHO 2008; 
RSA, NDOH/SANAC, 2010a).  As previously practised in South Africa, the first line 
drug regimen initiated with HIV positive children were Lamivudine, Stavudine and 
Efavirenz, however due to the side effects of Stavudine, it has been replaced by 
Abacavir as an alternative drug from the same class (RSA, NDOH/SANAC, 2010a; 
RSA KZNDOH, 2010).  For those already on the Stavudine, if lipodystrophy is 
suspected in a child, it is immediately discontinued and substituted with Abacavir 









Through viral suppression, this gives the body a chance to rebuild its immunity 
with progressive inclination of the CD4 cell count.  An adequate CD4 response for 
most patients on therapy is defined as an increase in CD4 count in the range of 50–150 
cells/mm3 per year, generally with an accelerated response in the first 3 months. 
Subsequent increases in patients with good virologic control show an average increase 
of approximately 50–100 cells/mm3 per year (Kaufmann et al, 2003).  After the first 
line anti-retroviral therapy implementation, the viral load should become undetectable 
(<40 copies/ml) on a 4-6 month follow-up (USA. DHHS, 2011). 
 
Virologic failure is the most common reason for treatment failure ie. an 
incomplete viral suppression, unsustained suppression or viral rebounding according to 
the DHHS ART Guidelines (USA. DHHS, 2013).  The criteria to determine treatment 
failure are clinical disease progression, lack of sustained immunological recovery and 
the viral load values (WHO, 2007).  The clinical category in determining treatment 
failure is the presence of recurrent opportunistic infections, loss of developmental 
milestones, growth failure or an additional disease from the same disease stage or a 
disease from the next disease stage.  Immunologic failure is determined by a confirmed 
return of CD4 percentage to the baseline or a drop in 50% of the CD4 percentage from 
its peak.  Virologic failure or failure of 1
st
 line regimen is classified as viral load >1000 
copies/ml when tested twice 3 months apart (RSA, KZNDOH, 2010).  A second line 
regimen is implemented if treatment failure occurs, therefore viral load testing on an 
internationally accepted 6 month interval is crucial to allow timely switching to the 









decision on when to switch from first-line to second-line therapy is critical as  too early 
a decision would mean that the months or years of potential further survival-benefit 
from the first line regimen is lost.  However, if it is made too late, the effectiveness of 
second-line therapy may be compromised and the patient is put at risk of a blunted 
recovery with increased mortality risk (WHO, 2007).  Adherence to treatment in a 
paediatric population is a more complex situation due to an array of factors than that 
experienced with adult populations (Haberer and Mellins, 2009).  The impact of non-
compliance and treatment interruption on viral load and CD4 count are serious 
consequences, which contributes to treatment failure and poor recovery on subsequent 
treatments thereafter (Tesiorowski, 2001). 
 
2.1.5  HIV Pathogenesis and Life Cycle 
 
 
There are currently two types of HIV strains identified that are pathogenic to 
the human species called HIV-type 1 and HIV-types 2.  The HIV-1, which is the more 
prevalent and virulent type is classified into 3 groups, M, N and O.  Of these three 
groups, M is the largest group made up of 9 clades or subtypes namely, A, B, C, D, F, 
H, J and K.  Subtypes E, G and I are classified as genetically mixed or recombinant 
forms (Levy, 2009).  The most prevalent subtype in the world and in Southern Africa is 
the subtype C.  Different subtypes are found to be the prevalent in different 
geographical regions across the world (BIPAI 2010, pp.7-14).  The HIV-1 transmission 
rate and the pathogenic course of disease progression to AIDS are much quicker than is 









1994).  The HIV-2 discovered approximately 2 years after the discovery of HIV-1 
(Clavel et al, 1986), is more frequent in regions of Central and Western Africa (Kanki 
et al, 1994; Fanales-Belasio et al, 2010; BIPAI 2010, pp. 7-14).  It is almost 
indistinguishable from the Simian Immunodeficiency Virus (SIV), which was found in 
its natural host, the sooty mangebey monkeys of West Africa (Dunham et al, 2006).  
The HIV originated from the SIV through animal-to-human (zoonotic transmission) 
from infected sooty mangabey monkeys to the human species (Hahn et al, 2000, BIPAI 
2010, pp. 1-6).  HIV belongs to the Lentivirus genus of the Retrovirus family (Fanales-
Belasio et al, 2010).  Typical of Lentiviruses, HIV exhibits a chronic insidious 
pathophysiological process of disease development with longer incubation periods and 
persistent viral replication (Fanales-Belasio et al, 2010). 
 
T-lymphocytes are types of white blood cells that are a critical component of 
the body‟s immune system and are the primary targets of the HIV (BIPAI 2010, pp.7-
14; RSA. NDOH/SANAC, 2010a).  The HIV is fragile and has a short life span outside 
of the host but once entry occurs, the HIV life cycle persists through a six-stage 
process.  The stages are binding and entry, reverse transcription, integration, 
replication, assembly, budding and maturation (BIPAI 2010, pp.7-14).  The external 
structure of a HIV virion is that of a spherical bi-lipid layered envelope consisting of 
numerous, paired glycoprotein spikes bound together on its surface (BIPAI 2010, pp.7-
14; Fanales-Belasio, 2010; Vogt and Moreno, 2012).  These two glycoproteins gp120 
and gp41 on the virus surface serve as detectors for susceptible host-invading cells 









CD4+ receptors on the surface of CD4+ lymphocytes similar to a lock and key fit and 
begin the process of host cell invasion (BIPAI, 2010, pp.7-14; Vogt and Moreno, 
2012).  Within the cytoplasm of the virus, are several accessory proteins that help the 
virion in numerous ways to carry out its functions to survive and proliferate (Stout et 
al, 2009).  
 
Within the core of the virus is a cone-shaped protein structured „capsid‟ 
housing the nucleocapsid layer that contains the RNA genetic material and the 3 most 
important triggering viral enzymes called reverse transcriptase, integrase and protease 
(Ganser-Pornillos, Yeager and Sundquist, 2008; Stout et al, 2009; BIPAI 2010, pp. 7-
14).  There are anti-HIV drugs that had been developed and currently are in use that 
block the action of these individual viral enzymes and are used in combination as a 
HAART regimen (Rathbun, 2011).  HIV being a retrovirus, is typically a ribonucleic 
acid (RNA) virus that survives by evolving to a stage where it uses the host cell‟s DNA 
that serves as the machinery to produce vital structural and functional components of 
the virus (BIPAI 2010, pp. 7-14).  However, unique from the genetic make-up of other 
retroviruses, HIV has 9 genes on two identical single stranded RNA that code for the 
all the necessary enzymes and proteins that make up a single virion (BIPAI 2010, pp. 
7-14).  HIV remains dormant within its host cell and only upon activation of the 
infected lymphocyte, would the HIV then commence the dynamic six-stage process 










2.1.6  Neuroinvasion by HIV and CNS Damage 
 
 
Invasion of the nervous system occurs in the early stages of HIV infection by 
infecting cells of the immune system (Powderly, 2000; Lindl et al, 2010).  Even in the 
presence of HAART, the pathological features of HIV encephalitis persists as found 
with post-mortem analyses (Masliah et al, 2000).  This only reinforces the mounting 
evidence that HAART is capable of controlling the disease but not eliminating it, 
especially in a sanctuary site like the CNS (Albright, Soldan and Gonzalez-Scarano, 
2003).  Progression to the CNS occurs very rapidly by crossing of the blood-brain 
barrier (BBB).  The BBB is in two anatomical places, the first one is between the blood 
within the cerebral capillaries and the brain tissue (parenchyma) and the second is 
between the blood and the CSF in the choroid plexus (Zhang and Tuomanen, 1999).  
The BBB, an important portal of entry for the virus into the CNS, is however a 
physical impediment to antiviral drug delivery, hence limiting HIV eradication from 
the CNS (Albright, Soldan and Gonzalez-Scarano, 2003).  The most common findings 
are that the infection of brain tissue occurs through cellular invasion by 
monocytes/macrophages, endothelial cells, astrocytes, microglia and CD4 
lymphocytes, with the perivascular macrophages as the undisputed virus-carrying 
invader of brain tissue (Davis et al, 1999; Johnson et al, 1996; An et al, 1999; Trillo-
Prazos et al, 2003; Lindl et al, 2010).  Macrophages are cells that are a vital component 
of the human immune system, which scavenge debri and primarily phagocytose 
foreign material and pathogens in the body (BIPAI 2010, pp. 7-14).  However, if 
infected by HIV, they have the potential to secrete neurotoxins that directly results in 









Oligodendrocytes which are glial cells that surround neurons to provide structural 
support and speed up electrical signals, have also been implicated as cells involved in 
CNS infection (An, Giometto and Scaravilli, 1996; Bissel and Wiley, 2004; Genetics 
Science Learning Center (GSLC), 2012). Microglia which are the brain‟s immune cells 
have similar functions to that of macrophages and they play a role in sustaining brain 
development and brain physiology and neural circuit functions (Gehrmann, 1996; 
Tremblay et al, 2011; GSLC, 2012).  Astrocytes, like microglia are glial cells that play 
a supportive role in maintaining structure of brain tissue with their long octopus-like 
processes (GSLC, 2012).  Newer studies have shown that beyond their primary role, 
they are also responsible for vital neural circuitry functions as they respond intensely to 
CNS injury (Sofroniew and Vinters, 2010).  Endothelial cells are cells that line blood 
vessel walls and are an important structural component of the BBB due to the tight 
cellular junctions that glues these cells together (Liu et al, 2002; Ballabh, Braun and 
Nedergaard, 2004).  The currently accepted hypothesis of neuroinvasion by HIV is 
through the „Trojan Horse‟ style of entry, were monocytes infected with HIV permeate 
through the BBB to enter the brain tissue (Liu et al, 2000; Bissel and Wiley, 2004).  
These infected monocytes later differentiate into macrophages (Albright, Soldan and 
Gonzalez-Scarano, 2003).  At this point of the neuroinvasion, the virus establishes its 
reservoir within the brain parenchyma and the perivascular macrophages where it 
remains latent, impervious to certain antiretrovirals.  Upon activation of the 
macrophage, begins the dynamic process of viral replication (Morris et al, 1999).  
Astrocytes, which are susceptible to HIV infection, appear not to be responsible for 









as cells involved in productive CNS infection (Gorry et al, 2003; Gonzalez-Scarano 
and Martin-Garcia, 2005).  The CD4 lymphocytes are initially involved in the 
transmission of HIV into the CNS however, they are not the primary cells responsible 
for a productive infection in the CNS due to their short life span.  Neurons are resistant 
to viral penetration and are not involved in viral production but they are destroyed due 
to host inflammatory reactions and the release of neurotoxins from viral proteins, an 
unfortunate consequence of the presence of the virus in the brain (McArthur et al, 
2003; Gonzalez-Scarano and Martin-Garcia, 2005; Kaul et al, 2005).   
 
The evidence-based consensus is that the brain macrophages and microglia are 
the most commonly infected cells in the CNS with high HIV-producing capabilities 
(Bagasra et al, 1996; Johnson et al, 1996).  These cells are responsible for mediating 
neurological disease through viral protein production and neurotoxins (Kaul and 
Lipton, 1999).  In a publication by Van Rie et al (2007), the differences between the 
CNS pathophysiology in HIV-infected adults and children have been tabulated.  A 
valuable  observation was that the target cells of HIV are similar but with astrocytes 
playing a more central role in the CNS infection in children than with adults (Van Rie 
et al, 2007).  Further research in HIV neuroinvasion at cellular and molecular level are 
needed as the pathophysiological processes involved, for some parts, remain enigmatic 
(Harrington et al, 2005).  This insight would be valuable in understanding the clinical 










2.2 Focussed Scholarship Review 
 
2.2.1 Neuro-Cognitive impairment in HIV Infection 
 
 
Human immunodeficiency virus invasion into the CNS is the aetiology of an 
array of neurological disorders collectively known as HIV-Associated Neuro-cognitive 
Disorders (HAND) (Lindl et al, 2010).  A key consequence of neuronal cell death and 
neurodegeneration is the development of HAND (Lindl et al, 2010).  HAND comprises 
of three syndromes namely, HIV-associated Asymptomatic Neurocognitive 
Impairment (ANI), HIV-associated Mild Neurocognitive Disorder (MND) and HIV-
Associated Dementia (HAD) being the most severe form of HAND (Foley et al, 2008). 
The diagnostic criteria that characterise HAND are motor, behavioural and cognitive 
deficits that occur in individuals that fall into any of the three stages of HAND (Kaul et 
al, 2005).  HIV-Associated Dementia is an AIDS-defining illness and has devastating 
consequences due to it being progressive and debilitating with cerebral and basal 
ganglia atrophy and diffuse white matter degeneration (Dal Pan et al, 1992). 
 
Subcortical dementia is a sequale of HAD given the fact that the virus 
preferentially targets the basal ganglia and the deep white matter of the brain 
parenchyma (Boisse, Gill and Power, 2008).  Neurocognitive factors that comprise of 
HAD are psychomotor slowing, changes in mood and anxiety levels, deficits in 
memory, verbal fluency, attention and information processing (Portegies et al, 1993).  
Systemic and CNS viral burden is a poor predictor of HAD and neurocognitive 









(McArthur, Brew and Nath, 2005).  Neuropsychologic testing and evaluation has been 
used as a reliable tool in confirming the diagnosis of HAD and in the response to 
antiretroviral therapy (Boisse, Gill and Power, 2008). 
 
With the introduction and combination therapy of antiretrovirals, systemic 
infection is adequately controlled with a significant decrease in the incidence of HAD. 
However, due to HIV-infected patients‟ longer life expectancy due to HAART, 
patients still suffered from HAND with an increase in the prevalence of HAD and 
more in the milder forms of HAND (Sacktor et al 2004; Antinori et al, 2007).  This is 
attributed to survival and persistence of HIV within the CNS compartment. 
 
 HIV classically affects immature brains in a different way than in adult brains. 
The condition that arises from the infection of developing brains is called HIV 
encephalopathy that is subdivided into static and progressive (Smith, Adnams and 
Eley, 2008).  The CDC has defined progressive encephalopathy which is the most 
severe form of encephalopathy as having microcephaly, or failure to attain, or loss of 
developmental milestones, or loss of intellectual ability and/or acquired abnormalities 
in gross motor skills (CDC, 1994).  Patients classified as having static encephalopathy 
display sustained and non-progressive abnormalities in gross motor functionality, 
learning abilities, or developmental delays in reaching the relevant milestones 
(Shanbhag et al, 2005),  The Department of Psychiatry in California looked at the 
impact of HIV-associated neuropsychological deficits on everyday functioning and 









cognitive abilities (Havens and Mellins, 2008).  The overall quality of life is 
compromised even with milder forms of HAND where activities of daily living are 
adversely affected (McArthur, 2004). 
 
 The white matter damage and volume reduction in brain matter is a common 
radiological feature seen in HIV infection. This is due to myelin sheath loss from 
neurons.  This common finding implies that there is a tendency for subcortical white 
matter atrophy in CNS infection by HIV (Foley et al, 2008).  The regions most 
commonly affected are the basal ganglia, deep white matter, hippocampus and cerebral 
cortex (Gorry et al, 2003).  With neuroimaging techniques, the hallmarks of basal 
ganglia calcification and deep central white matter lesions have been identified in HIV 
infection (Decarli et al, 1993).  From this consistent finding, reduction in specifically 
the caudate volume of the basal ganglia has been identified.  Kieburtz et al (1996) 
found that signs of reduction in fine motor dexterity, psychomotor speed, verbal 
fluency and auditory attention have been linked to caudate degeneration.  Children 
infected with HIV are at high risk for developmental delays and deterioration in their 
cognitive functioning and abilities (Zheng and Gendelman, 1997; Havens and Mellins, 
2008).  Developmental delays are frequent in the major domains of cognition, 
speech/language and motor functioning. (European Collaborative Study, 1990; Wolters 
et al, 1995; Coplan et al, 1998; Boisse, Gill and Power, 2008).  Children on HAART, 
generally function within normal limits and succeed in school but may exhibit subtle 
delays and deficits in selected areas (Frank and Foley, 1997) such as processing speed 










Risk factors for the development of neurologic disease in children include high 
CSF viral load and maternal high viral burden at the time of birth.  Major consistent 
differences in the neuropathology of children from adults in this HAART era are the 
frequent infection of astrocytes together with basal ganglia calcification and cortical 
atrophy (Tardieu et al, 2000).  HAART‟s neuroprotective benefits have shown through 
various studies with sustained improvement and recovery in adults in terms of 
neurocognitive functioning (Robertson et al, 2004). Unfortunately, little is known 
regarding the neurocognitive strengths and weakness in infected children and 
adolescents on HAART (Martin et al, 2006).  Longitudinal studies assessing the long-
term impact of HAART on the neurocognitive outcomes in infected children are still 
left wanting (Shanbhag et al, 2005).  Furthermore, a meta-analysis of five Paediatric 
AIDS Clinical Trials Group studies have shown that viral load and not CD4 counts 
were predictive of cognitive decline in children beyond the infancy stage (Lindsey et 
al, 2000) whereas Shanbhag et al (2005) demonstrated that viral load and CD4 count 
are marginally predictive of neurocognitive testing outcomes.  
 
2.2.2 Neural Control of Saccadic Eye Movements 
 
Saccadic eye movements are elicited by motorneurons that discharge a burst of 
action potientials initiating the excitory phase followed by an inhibitory tonic discharge 
to maintain and hold fixation on a target (Robinson and Fuchs, 2001).  For saccadic 









saccadic eye movements (Muri and Nyffeler, 2008).  The cortical and sub-cortical 
areas in the brain involved in saccadic control are the visual cortex in the occipital 
lobe, frontal eye fields (FEF), supplementary eye fields (SEF) and the dorsolateral 
prefrontal cortex (DLPFC) in the frontal lobe, parietal eye fields (PEF) in the parietal 
lobe, basal ganglia (BG), thalamus, superior colliculi and the brainstem in the sub-
cortical region as well as the cerebellum (Leigh and Zee 2006, pp. 3-19).  Each of these 
structures comprises of the neurocircuitry that work together to produce accurate 
saccadic function.  There are two major domains of saccadic eye movements: reflexive 
or involuntary and the voluntary type or volitional saccades (Muri and Nyffeler, 2008). 
 
The PEF is mainly involved in reflexive saccades to sudden stimuli presented 
in the environment and disengaging fixation for the reflex action to occur (Muri and 
Nyffeler, 2008).  The FEF are involved in initiation of an action for intentional 
saccadic movement of the eyes to a fixation target.  The FEF and superior colliculi 
work closely together in voluntary saccadic eye movements and memory-guided 
saccades.  Memory-guided saccades refers to saccadic movements that are initiated to a 
remembered fixation point which is kept in working memory even when that target is 
no longer present (Mitchell and Zipser, 2003).  The SEF function in a similar manner 
to FEF to control the coordinated gaze movements of both eyes and head (Martinez-
Trujillo, Wang and Crawford, 2003).  Neural recordings in the SEF are shown to be 
involved in activities that are related to both vision and saccades, where similar 
findings have been identified with the FEF and superior colliculi.  Newer research 









and complex involving executive cognitive functions as well (Stuphorn and Schall, 
2006). 
 
The DLPFC is connected to a multitude of functional areas in the brain.  These 
interconnections exists between the thalamus, parts of the basal ganglia (specifically, 
the dorsal caudate nucleus), the hippocampus, temporal, parietal, and occipital areas 
(Zelazo and Muller 2002, pp.445-469). The DLPFC serves as a crucial area responsible 
for executive functions such as motor planning, organization, and regulation.  Due to 
its varied interconnections, it integrates sensory and motor information with regulation 
of intellectual function (Zelazo and Muller 2002, pp.445-469).  The DLPFC is heavily 
involved in memory-guided saccade and inhibits reflexive saccades. 
 
The BG is a functional area located at the base of the cerebrum comprising of 
numerous nerve cell nuclei that is considered to be necessary for voluntary control of 
body movements among other functions.  The BG is composed of globuspallidus, 
substantia nigra, subthalamic nucleus and the striatum of which the latter is further 
sub-divided into the caudate nucleus and the putamen.  From clinical observations it 
has been reported that patients exhibiting excessive and retarded bodily movements 
were diagnosed with BG disorders.  Lesions in the BG lead to movement disorders 
ranging from the inability to initiate a movement to the inability to suppress an 
involuntary movement (Hikosaka, Takikawa and Kawagoe, 2000).  Patients with 
diagnosed BG degeneration and cerebellar lesions as is in those with Parkinson‟s 









output of the BG is directed to the brainstem, with significant communication with the 
superior colliculi.  Patients experience saccadic deficits with memory-guided saccades 
and visually-guided saccades in BG disorders.  In terms of saccadic function the BG 
facilitate eye movements by preventing the inhibition signals, allowing movement and 
secondly, to enhance the inhibition of saccadic eye movements (Hikosaka, Takikawa 
and Kawagoe, 2000). 
 
 
Figure 2.1: Illustration of the Saccadic Pathway extracted from an article by Gaymard (2012). 
Cortical and sub-cortical control of saccades and clinical application.  
 
 
2.2.3  Eye Movement Testing as a Tool in  Psychiatric and Neurodevelopmental  
Disorders 
 
HIV-infection can be associated with CNS involvement and changes in the 
neurobehavioural status, particularly in advanced stages of the illness (Bornstein et al, 









cognitive neuroscience as they have proven to be a very useful neuroscientific tool that 
has allowed the psychiatric researcher to examine relationships between the brain and 
behaviour and the development of psychopathologies (Beatriz, Velanova and Geier, 
2008).  Researchers have assessed eye movements in an array of psychiatric disorders 
such as Autism Spectrum disorder, Attention-deficit Hyperactive disorder, Childhood-
onset Schizophrenia, Tourette‟s Syndrome, Oppositional Deviant Disorder, Conduct 
Disorder and Obsessive Compulsive Disorder, to facilitate the understanding of the 
complex underlying neuropathophysiology of psychiatric disorders (Nanda, Van Der 
Stigchel and Sergeant, 2008).  Specifically, voluntary control of saccades is 
particularly sensitive to psychopathology (Sweeney et al, 2004).  Green et al (2007) 
further indicated that saccadic eye movement testing could be a useful tool in 
providing insight into the workings of the CNS in children diagnosed with Fetal 
Alcohol Spectrum disorders (FASD) (Green et al, 2007). 
 
 These findings may not necessarily be extrapolated to children and adolescent 
patients, since the clinical manifestation and aetiology of psychiatric disorders may 
differ between childhood-onset and adult-onset (Carlson, Bromet and Sievers, 2000).  
Eye movements themselves may differ substantially between children and adults 












2.2.4 Clinical Assessment of Oculomotor Function 
 
Assessments of eye movement functioning in a clinical setting falls into three 
categories of tests: gross observation, psychometric tests and electrodiagnostic tests 
(Maples, Atchely and Ficklin, 1992).  The latter two testing approaches are not 
routinely used in mainstream general practice but rather by practitioners whose focus is 
on paediatric, binocular vision and behavioural optometry.  
 
Gross observation methods referring to chair skill testing is more widely used 
due to it being the quickest method without additional devices or materials which do 
not form part of the essential equipment routinely used in optometric practices in South 
Africa.  The traditional gross observation methods used is where the examiner is seated 
at eye level in front of the patient holding two fixation targets approximately 40cm 
from the patient‟s midline.  The examiner then provides instructions to alternate 
fixation between the targets as it is held in the horizontal, vertical and 2 oblique 
positions (Griffin and Grisham 1995, pp. 17 - 28; Carlson and Kurtz 2004, pp. 57-58).  
This technique is merely descriptive and not easily quantifiable.  
 
Subjective tests developed by the Southern California College of Optometry 
(Hoffman and Rouse, 1980) and The Northeastern State University College of 
Optometry decided to improve on the traditional gross observation methods by 
developing assessment criteria and norms to standardise the testing (Maples, Atchely 
and Ficklin, 1992).  These improved subjective, observational tests are referred to as 









1988).  The SCCO test is similar to the NSUCO test which has four areas of 
performance for saccades and for pursuits that are scored out of a scale of five.  This 
was an improvement on the accuracy of measurement of oculomotor function (Maples, 
Atchely and Ficklin, 1992).  
 
The Visigraph devices and the Readalyzer are electro-oculographic tests 
(Orlansky et al, 2011) that use infrared emitters and detectors that are mounted onto 
goggles, which the patient has to wear during reading.  It assesses the number of 
fixations, regressions and the reading speed (Okumura and Laukkanen, 2011).  Since 
saccadic eye movements are made during reading, it is thus also assessing the quality 
of efficient saccadic eye movements.  These instruments, although useful and reliable 
as objective eye movement recording instruments, are expensive hence they are not 
widely used and may be difficult to use with early-school going children (Rouse 2006, 
pp.335-368). 
 
An alternative approach in oculomotor assessments is the use of psychometric 
tests that create a reading environment.  This class of tests are based on the principle of 
verbalizing numbers that are read as quickly as possible without the use of a finger to 
guide the reading (Orlansky et al, 2011).  Such tests based on this principle are the 
Pierce Saccadic Test, the King-Devick Test (K-D), New York State Optometric 
Association King-Devick Test (NYSOA K-D) test and the Developmental Eye 
Movement Test (DEM), which was later developed (Orlansky et al, 2011).  The K-D 









sideline screening tool for athletes with a concussion (Galetta et al, 2011).  The validity 
of some of the earlier visual-verbal tests were questioned due to the fact that they were 
unable to differentiate between problems of automaticity and oculomotor problems 
(Richman, Walker and Grazia, 1983).  Automaticity refers to rapid, accurate and 
effortless word identification at single word level (Hook and Jones, 2002) and in these 
psychometric tests, automatic naming or calling skills of numbers.  It was for this 
challenge that lead to the development of the DEM which differentiates oculomotor 
dysfunction from automaticity problems (Garzia et al, 1990).  The DEM test falls into 
the domain of Rapid Automatic Naming (RAN) tests where its purpose was to quantify 
the efficiency of saccadic eye movements based on the speed and accuracy that a series 
of single digit numbers could be recognized and verbalized (Rouse et al, 2004).  The 
DEM examines the time taken for numbers to be read out aloud vertically and then 
horizontally.  The errors made during the test are computed and used in the final 
calculation of the recorded times.  A ratio score is determined by taking the horizontal 
time and dividing it by the vertical time.  These four parameters are compared against 
the established norms of the test according to the chronological age of the child (Garzia 
et al, 1990) 
 
The instructions on the DEM test version 1 is quite clear that the child should 
not use their finger while reading but to only use read eyes.  The developers of the 
DEM reported that the test had good test-retest reliability for the horizontal and vertical 
times with fair-to-good reliability for the ratio scores (Orlanksy et al, 2011).  An 









symptoms that are associated with oculomotor dysfunction (Tassinari and DeLand, 
2005).  Another study concluded that the DEM test performance did not correlate well 
with saccadic eye movement skills but related more closely to reading performance 
and visual processing speed in a simulated reading environment (Ayton et al, 2009).  A 
study by the University of Melbourne that investigated the validity of the DEM as a 
clinical saccadic test, demonstrated results that argued against the DEM as an 
assessment tool for saccadic eye movements (Ayton et al, 2009).  The European 
Academy of Optometry and Optics conducted a study that examined the relationship 
between the objective and subjective evaluation of eye movements using the DEM and 
the Readalyzer.  The conclusion of this study was that the results pointed to the DEM 
remaining a valid test of ocular motility but that the correlation between the DEM and 
the Readalyzer decreased because of the different stimuli used in the different tests 
(Manzoli et al, 2010). 
 
A study that evaluated the repeatability of the DEM by conducting the test three 
times at separate visits concluded that clinicians should be „cautious‟ in using the DEM 
test in isolation in reaching a diagnosis (Orlansky et al, 2011).  Medland, Walter and 
Woodhouse (2010) in their study determined that the horizontal score may be a reliable 
measure of a child‟s visual processing speed and be used as a predictor of children at 
risk of developing reading problems.  This would imply that the DEM ratio, which is 
determined by the using the vertical and horizontal score, is a greater indicator of poor 










The following studies examined the use of the DEM test in their different 
populations.  A study on an Italian population of children that examined the validity of 
the DEM according to the four variables of the test as a function of the chronological 
age concluded that the DEM is a valid tool in differentiating ocular motility problems 
from naming problems in the developmental age (Facchin, Maffioletti and Carnevali, 
2011).  
A study on Spanish-speaking children tested whether the DEM scores changed with 
respect to language differences.  Even though the norms for the Spanish-speaking 
children in the six year old category were lower than in the standardised norm for that 
age, it concluded that the DEM appears to be a reliable tool regardless of the language 
of the population being examined (Fernandez-Velazquez and Fernandez-Fidalgo, 
1995).  A study on Portuguese children using the standard American table of norms 
showed that a large number of these children had oculomotor problems and/or 
automaticity problems that highlighted the need for specific Portuguese-speaking 
guidelines for Portuguese children.  It was further concluded that DEM scores might be 
affected by differences in language, educational systems and/or cultural differences 
(Bapista et al, 2011). 
 
Pang (2004), from his dissertation on the DEM test with Cantonese-speaking 
children, proposed new norms for children of this language population.  He further 
proposed an improved method of recording using a voice recording of the responses, 
which allow the examiner to re-listen and re-assess the recording times to enhance the 









performed better in the vertical and horizontal test as compared to the standard norm 
but the study further highlighted that differences in language, educational and cultural 
backgrounds were factors that contributed to variable performances in the test (Pang, 
Lam and Woo, 2010a).   
 
2.2.5 Eye Movement Analyses in HIV-Infected Subjects 
 
Due to the overlap between brain areas that control eye movements and that 
which are injured during HIV CNS infection, studies examining subjects with 
HIV/AIDS were conducted.  Beyond the structural damage that occurs with the central 
white matter and deep grey matter structures, functional abnormalities such as ADC 
are a common sequale (Sweeney et al, 1991).  Evaluating eye movements as part of 
neuropsychological assessments to study disturbances in attention and motor control 
that are early manifestations of HIV infection of the brain appeared to be a promising 
approach (Sweeney et al, 1991).  Tervo et al (1986) indicated that ocular motility 
abnormalities may be an early sign of HIV CNS infection which was also emphasised  
by Feldon (1990) at the International Neuro-Ophthalmology Symposium.  Ocular 
motility defects observed in HIV infected patients appeared to originate from 
brainstem compromise as initial clinical presentations in three patients (Hamed, Schatz 
and Galetta, 1988).  Other motility disturbances reported were primarily saccadic 
dysfunctions, pursuit dysfunctions and alterations in optokinetic nystagmus (Roig and 
Iranzo, 1996).  Sweeney et al (1991) concluded from their study on pursuits eye 









the HIV infected individuals prior to the establishment of the diagnosis of ADC.  This 
implied that pursuit dysfunctions could be an early indicator of CNS infection in HIV 
infected individuals.  Currie et al (1988) who focussed their study on saccadic eye 
movement functioning concluded that there was a correlation between saccadic deficits 
and the severity of ADC (Currie et al, 1988).  Most of these publications reporting eye 
movement dysfunctions were in the pre-HAART era and none of which were 























The methodology employed in this study was constructed to answer the primary 
research enquiry. 
 
3.1 METHODOLOGICAL FRAMEWORK 
3.1.1  RESEARCH QUESTION 
Could the detection of abnormal saccadic eye movements in children from 6 to 13 
years with HIV/AIDS on HAART, be a predictor of the status of their immune system?   
 
3.1.2 PRIMARY OBJECTIVES 
The primary objectives of this study were to determine the: 
1. Prevalence of saccadic eye movement abnormalities in HIV positive subjects 
on HAART 
2. Relationship between saccadic eye movement abnormalities and the 
immunologic (CD4 count) and virologic (viral load) indicators of HIV positive 
subjects. 
3.1.3 SUPPORTIVE INVESTIGATIONS 
 
The supportive investigations of this study were conducted to further explore the 
characteristics of this population to fully address the research enquiry.   The supportive 
investigations were to: 









2. Compare the prevalence of saccadic eye movement abnormalities between the 
different age groups of the study sample. 
3. Evaluate the subjects‟ performance in the DEM test against the age-specified 
standardized normative values. 
 
3.1.4 HYPOTHESIS 
Null Hypothesis (H0) Abnormal saccadic eye movements detected with the DEM 
test cannot predict the immunologic and virologic status of 
children with HIV/AIDS on HAART.  
 
         Alternate Hypothesis (Ha)  Abnormal saccadic eye movements detected with the DEM 
test can predict the immunologic and virologic status of 
children with HIV/AIDS on HAART.  
 





















This study was epidemiological in nature that described the population of 
HIV/AIDS subjects on HAART.  By investigating saccadic abnormalities, the 
researcher aimed to observe and describe the findings of the specified population in 
terms of eye movement performance without attempting to affect a change or use 
interventional methods to alter the characteristics of the population.  The study was 
prospective where the subjects were individually tested with the DEM test from which 
conclusions about the population was drawn from the results.  A cross-sectional design 
was adopted as the subjects were utilized only once and were not revisited.  The DEM 
test was performed once and the results were compared against the latest immunologic 
and virologic findings of the subjects that were available at the time of the data 
collection.  
Method of Data Collection 
Simultaneous observation of the subjects by the researcher when the DEM test was 
conducted. 
 
3.1.6   INCLUSION CRITERIA 
 
 Children from the ages of 6 years to 13 years and 11 months were included in 
this study provided they met the criteria listed below:  
o Infected with HIV 
o HIV type 1 strain infection only 









o Visual identification and verbalisation of numbersNear visual acuities 
of 6/9 and in each eye 
3.1.7   EXCLUSION CRITERIA 
 
 Subjects with HIV type 2 strain. 
 Subjects with HIV type 1 & HIV type 2 infections. 
 Illiterate subjects 
 Subjects non-verbal in English 
 Subjects on different ARV drug regimens 
 Learning disabilities 
 Subjects with: 
o Near visual acuity worse than 6/9 
o Strabismus 
o Extra-ocular muscle nerve palsies 
o Eye infections  
o Recently acquired HIV infections 
o  Neurological diseases or disorders 
 Subjects previously diagnosed and with existing psychiatric and 
neurodevelopmental disorders. 
 Subjects previously diagnosed and existing central nervous system 












3.1.8  STUDY POPULATION 
 
Children with HIV/AIDS on HAART from 6 years to 13 years and 11 months of age 
living in the Motheo and Xariep district of the Free State province were accessed from 
8 data collection sites.  
 
3.1.9  SAMPLE SIZE 
 
One hundred and twenty eight (128) HIV positive children made up the final study 
sample.  There were 185 subjects accessible to the researcher during the sample 
selection phases at the data collection sites of which 57 subjects did not meet inclusion 
criteria.  According to the estimated number of subjects attending the data collection 
sites, a projected number of fewer than 200 subjects were targeted. This sample 
number was determined conveniently, as this was the ideal approach due to time 
availability and direction from the biostatistician. 
 
 There were unforeseen additional factors that warranted exclusion from the final 
sample pool outside of what was specified in the exclusion criteria.  These additional 
unforeseen factors were incomplete or missing CD4 count and viral load data from the 
health records and absence of blood results due to testing not being done at a specific 
time.  Attempts were made to acquire some of the information from the NHLS but with 














3.1.10 SAMPLING METHOD 
 
 
Convenient sampling  
One hundred and twenty eight HIV positive children who presented at the data 
collection sites for their routine treatment and health assessments were included in the 
study.  This sample that was drawn was based on health record information and vision 
screening results all of which satisfied the inclusion criteria of this study.  As this was a 
non-random sampling method, no statistical formulae was required to draw a sample 
from the population.  
 
All 128 subjects were on HAART and none of the subjects used English as their home 
language.  All subjects were of African origin and were Sotho and Afrikaans home 
language-speaking individuals.  All subjects were however familiar with English and 
performed the DEM test by verbalizing the numbers in English as a standard. 
 
3.1.11 SAMPLE SELECTION PROCESS 
 
Phase 1:  Review of health records to extract relevant data and investigate for the 
factors that warrants exclusion. 
Phase 2: Subjects selected from phase 1 underwent a vision screening process to 
identify suitable candidates that satisfy the inclusion criteria and exclude those that did 
not fulfil the selection criteria 
Phase 3: Subjects that were successful from phase 2 comprised of the final study 









Phase 1: Subject Recording Form (Appendix A) was used for all subjects. 
1. Review of health records to assess for exclusion factors and to extract the 
relevant data such as:- 
 Personal details 
 Demographic information 
 Mode of transmission 
 Date of confirmed HIV infected status 
 Latest CD4 count and Viral load values 
 History or current systemic illness, neurological disease or disorders 
 Number of previous hospitalisations 
 Current ARV medication  
 Any non-ARV medication 
 Date HAART was initiated. 
 
Phase 2: Appendix A was used for all subjects selected at the end of phase 1.  
Informed consent (Appendix B and C) was requested from the care-givers of the 
prospective subjects in order to participate in phase 2. 
The following evaluations were conducted:- 
 Distance and near visual acuities 
 Retinoscopy  
 Distance and near cover test 
 Motility testing of pursuits, saccades and ductions 










 Knowledge of numeracy  
 
Phase 3: DEM test and scoring sheet was used for subjects that passed the criteria in 
phase 2.  The final results were recorded of the prepared DEM score sheet. 
The following steps of Phase 3 were followed:- 
 The DEM test was placed in front of the subject. 
 The pre-test was explained and then the subject was allowed to perform the pre-
test. 
 Once the subject was familiar with the test, the main DEM test was carried out. 
 The time taken by the subject to carry out Test A, Test B and Test C was 
recorded and the subject was released. 
 
3.1.12  DATA COLLECTION SITES 
 
The data collection sites were classified as ARV treatment centres (centres that 
dispense ARV medication to HIV-infected patients) in the province.  They were 
(conveniently) purposefully selected according to the knowledge that they have a 
greater access to HIV positive children and better accessibility for the researcher.  As 
the environment of the data collection sites were homogenous, generalized conclusions 
were made about the data.  The nearest site was 9 km from the location of the 









Motheo District in central Free State and 2 sites from the Xariep District in the 
southern Free State.  
 
List of data collection sites: 
1. Manguang University Community Partnership Programme (MUCPP) Centre – 
Motheo District, Bloemfontein 
2. Batho Primary Health Care (PHC) Clinic - Motheo District, Bloemfontein 
3. Pelonomi Regional Hospital - Motheo District, Bloemfontein 
4. Bloemspruit PHC Clinic - Motheo District, Bloemfontein 
5. Botshabelo Hospital – Motheo District, Botshabelo 
6. J.S Moroka Hospital –Motheo District, Thabanchu 
7. Petrusburg PHC Clinic –Xariep District, Petrusburg 























Figure 3.2: Map of the Free State Province indicating the towns where the data 




3.1.13 DATA COLLECTION INSTRUMENTS 
 
 
 Developmental Eye Movement Test:- 
To answer the research question most appropriately, the DEM test was selected to be 
the instrument of choice. 
 Motivation 
This type of test is claimed to be a valid instrument that is suitable for assessing 
eye movements in children by its developers and later by other researchers as a 
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superior test to its predecessors ie. Pierce Saccadic Test, the King-Devick Test (K-
D) and the New York State Optometric Association King-Devick Test as it is able 
to effectively differentiate oculomotor dysfunction from automaticity problems.  
 
The procedure of the DEM test is least invasive for a study sample of minors.  It is 
less intimidating and less novel to a child‟s experience in his/her environment as 
these are school-going children that are currently literate and perform reading 
skills. 
 
The duration of the DEM test and interaction with the subjects did not exceed 10 
minutes making it least imposing to the subjects.  
 
This test could be performed in any environment that is familiar to a child without 
any specific room or surroundings.  In this study, the test was performed with the 
subjects seated at a table in the clinic or hospital where they receive their 
medication or other treatment when needed.  
 
This test is not an automated device that is dependent on other factors for its 
functioning carrying minimal risk to the subjects. 
 
 Components of the DEM Test 
  Booklet – version 1, 1987.  Developed by Jack E. Richman 









Bernell. It is 265mm x 215 mm in dimensions. Booklet 
comprises of 6 ring bound cards of which the first is the cover 
followed by the pre-test, vertical Test A, vertical Test B, 
horizontal Test C and the lastly the DEM Normative Table for 
the vertical time, horizontal time, errors and ratio for age groups 
from 6 years to 13 years and 11 months. 
 DEM Score Sheet– This score sheet has Test A, B and C 
presented together on one sheet for the assessor to follow during 
testing.  It has areas to capture the times of these tests as well as 
the errors and the ratio.  
 
 Subject Recording Form (Appendix A) – This form was used to capture data 
collected from phase 1 and phase 2 by the researcher.  This form 
contained the demographic information, medical history and current 
health status (CD4 count, viral load and ARV treatment) of the subjects 
as well as the results of their vision screening. 
 
3.2 DEVELOPMENTAL EYE MOVEMENT (DEM) TEST 
Description, Procedure, Analysis, Interpretation and Characteristics 
 
3.2.1  DESCRIPTION 
 
There is a pre-test consisting of 10 single digit numbers in a row in a random order. 









each arranged in 2 vertical columns of 20 digits. The two columns are 98mm apart. 
The horizontal test (Test C) comprises 80 single digit numbers arranged in a horizontal 
array of 16 rows of 5 single digits each.  Test C is a sequential array of digits of Test A 
followed by digits of Test B but set out in a horizontally. The spacing between each 
digit in a row is not equal from row to row.  
The vertical time represented the baseline performance and determined automaticity of 
number calling.  The horizontal test assessed number calling skills but in a horizontal 
spatial array where adequate saccadic ability and oculomotor skill was required.  The 
child is encouraged to read without using their finger to guide them but instead to 
merely follow with their eyes as they verbalise the numbers 
 
3.2.2  PROCEDURE 
 
The researcher was seated next to the subject at a table with the DEM test 
approximately 30cm in front of the subject.  The procedure of the test was carried out 
as specified in the DEM test manual (Richman and Garzia, 1987). 
 
(start) Pre-test → Test A → Test B → Test C (end) 
 
Step1: The researcher asked the subject to carry out the DEM Pre-test (Figure 3.3) 
prior to performing the main DEM test.  The subject was expected to read out aloud the 
single digit numbers as fast and accurately as possible on the pre-test.  The pre-test 
assured the examiner that the subject was familiar with the numbers and instructions. 










Figure 3.3: The DEM Pre-test. Extracted from the DEM test (Richman and Garzia, 1987). 
 
Step 2: The examiner then had the child to complete Test A (Figure 3.4).  The subjects 
were then timed with a stopwatch and the duration of time taken to complete Test A 










Figure 3.4: The DEM Test A. Extracted from the DEM test (Richman and Garzia, 1987). 
 
Step 3: The subject was then prompted to perform Test B (Figure 3.5) in the same 
manner that Test A was done.  The time was recorded with a stopwatch and written 












Figure 3.5: The DEM Test B.  Extracted from the DEM test (Richman and Garzia, 1987). 
 
Step 4: In this final step, Test C (Figure 3.6) was carried out after an instruction was 
given on how to perform this horizontal test as it looked different from Test A and B.  
The subject was asked once again not to follow each digit using a finger.  While the 
horizontal test was being carried out, the examiner carefully followed on the DEM 
Score Sheet and highlighted the errors that were made as the subject verbalised the test.  
There were different types of errors that were made which this test defines and 










Figure 3.6: The DEM Test C. Extracted from the DEM test.(Richman and Garzia, 1987) 
 
3.2.3 ANALYSIS: TEST SCORE CALCULATION 
 
Errors:  There are four types of errors.  The errors that the DEM took into account 
were omission (o), addition (a), substitution (s) and transposition (t).  Omission refers 
to numbers that have been left out or skipped during the test.  Additions refer to new 
numbers added to the list of numbers in a row. Substitution refers to calling out of 









Transposition refers to the reading out-of-sequence of the numbers in a row.  Errors 
made in the vertical tests are ignored as they are a rare occurrence.  Only errors made 
with the horizontal test was recorded and used in the determination of the adjusted 
horizontal time. 
 
Vertical time: The two vertical scores/times (Test A and B) are added together to 
derive the total vertical time in seconds.  There was no adjustment of the vertical time 
as was with the horizontal time. 
 
Adjusted Horizontal Time: The horizontal time (Test C) was converted to a more 
reliable „adjusted horizontal time’ by compensating for the presence of errors made 
during this Test C.  The adjustment was established by decreasing the original 
horizontal time when numbers are added and increasing the time when numbers were 
omitted.  Omissions and additions were the only type of errors used in the calculation 
of the adjusted horizontal time.  Since there were 80 digits of Test C, this number was 
used in the calculation to produce a more accurate reflection of the horizontal time of 
the subjects. 
 
Calculation is as follows: 
Adjusted Horizontal Time = horizontal time (sec) x [80/80 –o+a)] 
o = omission, a = additions 
Ratio: A ratio score was calculated by dividing the adjusted horizontal time by the 










Figure 3.7: The DEM Score Sheet extracted from the DEM test (Richman and Garzia, 1987)   
 
The DEM Score Sheet (Figure 3.7) which was used by the researcher to follow as the 
subject performed the tests.  The recordings and calculations were done at the bottom 









3.2.4  INTERPRETATION OF BEHAVIOUR TYPES 
 
The clinician must then consult the normative tables that were established for each age 
category to determine if the subjects‟ total vertical time, adjusted horizontal time, ratio 
score and errors are within the DEM standard norm.  For clinical purposes and 
interpretation, the results of the subjects have been categorised into one of four 
“behaviour types” (Table 3.1) based on the DEM normative scale. 
 
Table 3.1: List of behaviour types with the rating of their vertical time, horizontal time and 
ratio. 
Behaviour Type Vertical Time Horizontal Time Ratio 
Type 1 normal normal normal 
Type 2 normal high high 
Type 3 high high normal 
Type 4 high high high 
 
 
Table 3.2: Non-standardised behaviour type that is not specified in the DEM test. 














3.2.5  CHARACTERISTICS OF BEHAVIOUR TYPES 
Behaviour Type 1 showed normal performances in both the vertical test and horizontal 
test within the norms and standard deviations for their age.  This resulted in a normal 
ratio. This behaviour type means that there were no oculomotor abnormalities or 
automaticity problems manifested with the DEM test. 
Behaviour Type 2 comprised of subjects with normal vertical times and abnormally 
high horizontal times meaning their times were significantly increased above the norm.  
This would mean that the resultant ratio would be higher than the norm for their age 
category.  This was interpreted according to the DEM test, as having problems with 
oculomotor function as opposed to automaticity skills. 
Behaviour Type 3 is a category with an abnormal increase in both vertical and 
horizontal times but with a resultant normal ratio. This represented problems in 
automaticity or specifically in number calling skills. 
Behaviour Type 4 is characteristic of subjects with increased vertical and horizontal 
times and with an abnormally high ratio.  This indicated the subjects with deficiencies 
in both automaticity and oculomotor skills. 
Behaviour Type 5 is a new category that is unlisted in the standardized DEM test.  
Even though the DEM specifies only four behaviour types there are other occurrences 
that are not classified in the DEM test by its developers.  Subjects could have a high 
baseline performance ie. increased times with the vertical test but better and quicker 
times with the horizontal test.  This was an unusual scenario as the horizontal test 
would characteristically take a longer time.  This occurrence would then result in a low 









Type 5.  This type of behaviour is similar to behaviour type 3 with respect to the ratio, 
which is normal.  The implication of this type of behaviour is that automaticity 
deficiencies many still be the causative factor as opposed to eye movement problems 
as poor vertical times is a direct indicator of automaticity problems 
 
Table 3.3 summarises the interpretation of the performances in the vertical and 
horizontal times and the resultant ratio that defines the behaviour type based on those 3 
parameters as having normal automaticity skills and oculomotor skills, oculomotor 
dysfunction, deficient automaticity or a combination of deficient automaticity and 
dysfunctional oculomotor skills.  Errors that were made during the testing were not a 
parameter that was used in the determination of a diagnosis or specification of a 
behaviour type. 
 
Table 3.3: A summary of the list of behaviour types with a primary description of the 
characteristics that define them. 
Behaviour Type Characteristic 
Type 1 Normal automaticity and oculomotor skills 
Type 2 Oculomotor dysfunction 
Type 3 Deficiencies in automaticity/number calling skills 
Type 4 Deficiencies in automaticity and oculomotor skills 











3.3  DATA ANALYSIS 
 
The data analysis was prepared by a biostatistician based at the Department of 
Biostatistics at the University of the Free State. 
The statistical system used was the Statistical Analysis Software (SAS) version 9.2. 
Specific statistical methods employed were dependant on the characteristics of the 
collated data as well as the best tools to express outcome of the hypotheses. 
 
Below is a systematic overview of the analyses that were conducted:- 
 A demographic profile of the sample was conducted using descriptive 
statistics to describe the frequencies (counts) and relative frequencies 
(percentages) of the categorical data such as gender and the frequency of 
subjects at the various data collection sites.  Descriptive statistics were also 
used to express the numerical data of the age ranges of the sample through the 
expression of mean median and standard deviation.  
 
 A clinical profile of the sample was described using descriptive statistics to 
express the numerical data presented in tables, which evaluated the:-  
o Time frame from birth until diagnosis of HIV infection was confirmed 
o Time frame from birth until HAART was initiated 
o Time frame from diagnosis until HAART was initiated 
o Duration on HAART 
o CD4 count distribution in the sample 









o CD4 count distribution across the different age groups 
o Viral load distribution across the different age groups 
 
Non-parametric statistical methods were used to express the relationship between the 
variables as no distributional assumptions were made.  
 
o A correlation analysis was conducted between the continuous variables of 
CD4 count, viral load, treatment duration and CD4 percentage, which were 
expressed using Spearman’s Correlation Coefficient.  Spearman 
Correlation Co-efficient was preferred over Pearson Correlation Co-
efficient for non-normally distributed data and since a prediction of 
linearity between two variables was not one of the expectations, 
Spearman‟s was the better method of analysis. 
o  Hypothesis testing was done to validate or invalidate the claim, which was 
made with the null hypothesis.  The precision of the estimates were 
assessed using 95% confidence intervals.  If p >0.05, this indicated weak 
evidence against the null hypothesis hence failure to reject the null.  If p < 
0.05, this indicated strong evidence against the null hypothesis hence it 
would be rejected.  Statistical significance was implied indicating that some 
other factor besides chance was operating for the difference between the 
expected and the observed data to be so great. 
o In this study the variables have been proportioned into specified categories 
were their associations were examined with Chi-square tables.  Statistical 









through the Chi Square Test as well as the Fisher’s Exact Test where the 
status of the hypothesis was determined.  For computation of the p value, 
where the Chi-square had a larger distribution of cells with counts less than 
5, the Fisher‟s Exact test was used.  As a rule of thumb, for deciding 
whether the Ch-squared approximation is good enough, the Chi- square test 
is not suitable when the expected values in any of cells of the table are less 
than 5.  The Fisher‟s exact test is one from a class of „exact tests‟ where the 
significance of the deviation between the observed and expected from the 
null hypothesis can be calculated exactly where the absolute p value is 
expressed.  The exact p values were given for the benefit of the reader.  It is 
useful for categorical data and examines the significance of the associations 
between different categorical variables.   
 
 A DEM analysis profile was done on the results of the DEM test.  The 
analysis was as follows:- 
o Vertical time, horizontal time, ratio and error scores of the full sample 
were examined to determine the percentage of subjects that fell outside 
of the DEM standards. 
o Vertical time, horizontal time, ratio and errors scores where 
categorically expressed across the age groups and was simultaneously 
compared against the DEM age-specific norms. 
o The behaviour types where expressed from the results of the vertical 









o The prevalence of the different behaviour types across the sample was 
determined.  
o The viral load and CD4 count where independently put into three 
categories based on levels of severity in terms of quantity of the virus in 
the blood and in terms of strength of the immune system using the CD4 
count values. 
o The relationship between the two disease parameters where investigated 
with the Chi Square Test and the Fisher‟s Exact Test. 
o The relationship between the behaviour types and the viral load and 
between the behaviour types and CD4 count categories were performed 
using a Chi Square Test.  Fisher‟s Exact Test was further employed to 
determine probability.  
o The prevalence of the different behaviour types in the different age 
categories were graphically represented and compared for assessment of 
trends from which conclusions. 
 
3.4  ETHICAL REVIEW 
 
An expedited ethics review was requested by the University of Kwa-Zulu Natal 
Biomedical Research Ethics Committee after submission of the research proposal.  
This type of review was requested as there were no invasive procedures to be 









requested prior to the final granting of full approval (Ethical Approval Number: 
HSS/0446/2010 M: Faculty of Health Sciences). 
 
The participation of minors in this study was indispensable as this research and 
the instrument (DEM Test) was of relevance to children and could not be carried out 
with adults.  
 
This study is classified as „non-therapeutic‟ as by definition this intervention 
does not hold out the prospect of direct health-related benefit for the participant but the 
results produced may contribute significantly to knowledge in the general specified 
population regarding about the condition of these subjects (RSA. NDOH, 2004).  
 
In terms of „risk‟, this study places the participant at no more than minimal risk, 
which is also referred to as „negligible risk‟.  Minimal risk is defined as that which is 
commensurate with daily life or routine medical or psychological examinations (RSA. 
NDOH, 2004). In this study no harm or discomfort was brought to the subjects as all 
procedures that were done on the participants are that which are routinely done in a 
basic eye examination along with the DEM test which was simply a reading test.  All 
tests were non-invasive with no direct discomfort to the eyes.  No pharmaceutical 












3.5  ETHICAL CONSIDERATIONS 
 
 
3.5.1 Informed Consent 
 
Signed informed consent was obtained from all parents/guardians of the 
subjects (Appendix C).  The adults responsible for the subjects were given information 
on an information sheet (Appendix B) which stated the aim of this study, the requests 
of the researcher and the expected role of the subjects in this study.  Consent was stated 
as voluntary and no subjects were victimized if participation was refused as subjects 
and their caregivers were granted autonomy and were under no obligation to 
participate.  The subjects had the right to withdraw from the study at any point and 
could request that their data not to be used.  The presence of the adult responsible for 
the subject during the data collection process was also welcomed.  This additional 
information was included in the information sheet. The consent form and information 
sheet was produced in three languages ie. English (B1,C1), Afrikaans (B2,C2) and 
Sotho (B3,C3) and was given to the respective care-givers in their preferred language. 
 
3.5.2  Patient Confidentiality 
 
The confidentiality of the subjects were upheld as no names were be used in the 
data collection form, but a code for each subject was allocated.  There was a 7-digit 
code developed for each subject.  The first 3 digits were abbreviations of the data 
collection site that the subject was examined at.  The next 2 digits were the first letters 
of the subjects‟ surname and first name and the last 2 digits represented the number 









duplication of the subject codes and this was the manner in which the data of each 
subject was captured electronically. 
 
The confidentiality of the subjects‟ health status and their medical history was 
also maintained as the knowledge of such was only held by the researcher who was the 
only data collection personnel along with the nursing staff that provided assistance 
during the process.   
 
3.5.3  Moral Considerations and Conduct 
 
Regardless of how the subject performed during the screening and the DEM 
testing phases, positive re-enforcement was used with every subject.  There was no 
negative information or comments given to the subject during the data collection 
process.  
 
Even though the researcher was under no obligation, every parent and guardian 
that accompanied the subjects on the day of data collection was given general feedback 
on the overall condition of the subjects‟ eyes.  All subjects were advised to come for an 
eye exam once a year but if problems with their eyes occurred at any point, they should 
come as soon as possible to seek medical attention.  
 
When there were subjects that co-incidentally were found to require further 









within the expertise of the researcher.  Alternatively, they were referred to the National 
Hospital Optometry Clinic in Bloemfontein for further intervention or referred 
internally to the attending doctor at the data collection site.  
 
3.5.4  Administrative Obligations 
 
 
A letter of request to the provincial Head of Health in the Free State was 
submitted prior to commencement of the data collection process. This letter briefly 
explained the nature of the study and a request to use the indicated health facilities as 
the data collection sites. Approval was subsequently granted with recommendations 
(Appendix D). 
 
3.6  METHOD OF REFERENCING 
The citations and referencing in this study was done according to the Harvard  system 




















This chapter presents the results of the study by initially describing the study 
sample.  This is followed by an in-depth analysis of the data with specific focus on the 
objectives and the supportive investigations that were conducted to address the 
scientific enquiry.  The chapter concludes with a summary of the results presented. 
 
4.1 DEMOGRAPHIC PROFILE 
 
The data to follow under this section represents the frequency (absolute value) 
of subjects at the different data collection sites as well as the gender and age 
distribution of the sample. 
 
 


























Figure 4.1 demonstrated that there were 69 (54%) subjects seen in the three 
hospitals with the remaining 59 (46%) subjects accessed from clinics.  Most of the 
subjects came from Botshabelo Hospital in Botshabelo and J.S Moroka Hospital in 
Thaba‟nchu making up 52% of the total sample.  There were 23(18%) subjects seen in 
the Xariep District and 82% of subjects were from the Motheo District.  None of the 
subjects from these areas used English as their home language. 
 
Table 4.1: Gender distribution of the total sample 
GENDER DISTRIBUTION 
N Gender Frequency (n) Percent (%) 
128 Male 61 48 
Female 67 52 
 
An almost even distribution of gender differences as shown in table 4.1 was not 
an intentional desire for the sample as is shown in Table 4.1, however the final sample 
pool shows a close to even gender spread across the sample of subjects.  The ratio of 
male to female subjects selected, quite closely resembles the 1:1 ratio of the gender 
distribution of children aged 0-14 years in the Free State province (Statistics SA, 
2012a).  
 
Table 4.2: Represents the summary statistics of the age variable 
AGE 
N Mean Median Minimum Maximum 
128 10yrs and 1 
month 
8yrs and 6 
months 
6yrs and 9 
months 











N Mean Median Minimum Maximum 
(121 months) (102 months) (81 months) (167 months)  
 
 
In table 4.2, the mean (10yrs + 1 month) quite closely matches the centre value of the 
spread (median).  The minimum age ranged from 6 years 9 months to 13 years 11 
months as the maximum age, which was the restriction placed on the sample drawn 
from the population due to the DEM test only being applicable to candidates up to 
13years and 11 months. 
 
Table 4.3: The distribution of the ages in the sample ranging from  6 to 13 years and 11 
months. 
AGE DISTRIBUTION 
Age Frequency (n 
= 128) 
Percent (%) 
6 (0 – 11 months) 4 3 
7 (0 – 11 months) 13 10 
8 (0 – 11 months) 24 19 
9 (0 – 11 months) 30 23 
10 (0 – 11 months) 16 13 
11 (0 – 11 months) 11 9 
12 (0 – 11 months) 17 13 











Table 4.3 has shown that a large proportion of subjects were 9 years old (23%) with 
only 3% of subjects at age 6 years of age.  The majority of the subjects were from 8 to 
10 years of age (55%) 
 
4.2 CLINICAL PROFILE 
 
This section comprehensively describes the clinical profile of the sample using 
summary statistics by examining the virologic status, immunologic status as well as the 
diagnosis and treatment timelines ranges for each of the subjects.  The data to follow 
are represented with tables expressing the time taken till the diagnosis of HIV infection 
was confirmed, the waiting period until treatment was initiated, the duration of subjects 
on HAART as well as the CD4 count and viral load distribution across the sample.  
More focused expression of the data regarding the viral load and CD4 count variables 
had been described for each age group.   The second section presented the correlation 
analyses between the parameters of viral load, CD4 count and treatment duration.  
 
4.2.1 Description of Variables 
 
Table 4.4: The summary statistics of the time period from birth until a diagnosis of HIV 
infection was confirmed.  
TIME FRAME FROM BIRTH UNTIL DIAGNOSIS CONFIRMED 
N Mean Std. Dev. Median Minimum Maximum 





6yrs 1 month 
(73 Months) 











The average time taken for the diagnosis to be confirmed as shown in table 4.4 
was 5 years and 10 months with a centre value of 6 years and 1 month.  This analysis 
was based on only 81 of the 128 subjects as there was insufficient data available in the 
remaining 47 subjects‟ health records of when the diagnosis was established.  
 
Table 4.5: The summary statistics of the waiting period from diagnosis to the initiation of 
HAART  
PERIOD FROM DIAGNOSIS TILL INITIATION OF TREATMENT 
n Mean Std. Dev. Median Min Max 
79 2yrs 7 months 
(19.1 Months ) 
2 yrs 
(24.5 Months)  
9.0 Months 0 10 yrs 7 months 
(127 Months) 
 
The numerical data displayed in table 4.5 is a description of the time frame for 
only 79 of the 128 subjects as the time of diagnosis was not always specified for all 
subjects in the subjects‟ health records.  With the centre value (median) being a low 9 
months as compared to the mean of 19.1 months, this indicated that 50% or more of 
the 79 subjects were put on HAART in under 12 months of being diagnosed. 
 
Table 4.6: The summary statistics of the waiting period from birth to the initiation of HAART  
PERIOD FROM BIRTH TILL INITIATION OF TREATMENT 

















Both the mean and median time from a sample of 127 subjects indicated in table 4.6 
that approximately 7 yrs (6yrs and 11 months) would be the waiting period that an HIV 
positive child from this sample had waited to be treated with HAART (Table 4.6).  
 
Table 4.7: The summary statistics of the duration of HAART in the subjects 
DURATION ON HAART 
n Mean Std. Dev. Median Min Max 
12
7 












The expression of the numerical data on the treatment duration variable ranged 
from 4 months up to 7 years and 8 months as shown in table 4.8.  This represented a 
sample with uninterrupted treatment with the specified 3 drug regimen.   The median 
and the mean are almost the same, which indicated a gradual climb from the minimum 
to the maximum duration time.  
Table 4.8: The length of time at which each age group was on HAART 
TREAMENT DURATION (MONTHS) ACROSS THE AGE CATEGORIES 
OF THE SAMPLE  
Age n Mean Std. Dev. Min Max 
6yrs 3 46.67 ±28.75 16 73 
7yrs 13 44.15 ±24.94 4 79 
8yrs 24 42.04 ±24.59 6 90 









TREAMENT DURATION (MONTHS) ACROSS THE AGE CATEGORIES 
OF THE SAMPLE  
Age n Mean Std. Dev. Min Max 
10yrs 16 40.19 ±28.21 5 92 
11yrs 11 34.55 ±20.30 8 73 
12 yrs 17 29.53 ±24.25 5 83 
13yrs 13 35.00 ±22.32 5 76 
  
Table 4.8 displays the numerical data of the treatment duration of subjects in 
the sample according to the different age groups. The pool of 6 year olds had the 
longest average time on HAART (46 months). Subjects in the 12 year old group with a 
frequency of 17 subjects averaged the lowest duration on HAART (29 months). By 
close inspection of all the means in the different age groups, children who were in the 6 
and 7 year olds‟ age groups were the longest on HAART whereas the subjects in the 12 





















Table 4.9: The distribution of the CD4 counts across the sample. 
CD4 COUNT DISTRIBUTION 
Immunologic 
Categories 


















≥ 500 100 78.1 
 
    
The CD4 count range was broken up into 3 categories abridged from the CDC 
classification of infection control and shown in table 4.9 above.  Seventy eight percent 
(78%) of subjects are within the 3
rd 
category, indicating that over 3 quarters of the 
sample had an immune system that is being sustained within a normal range due.  Any 
absolute CD4 count ranging from 500 cells/mm
3
 to 2010 cells/mm
3 
is taken to be a 
normal quantity of CD4 lymphocytes in serum.  Only 5% of the sample was found to 
have counts of less than 200 cells/mm
3
, implying that these subjects would be highly 
vulnerable to opportunistic infections and sporadic viral proliferation due to a severely 













Table 4.10: the summary statistics of the CD4 count and percentage across the sample. 
CD4 COUNT SUMMARY 





815.73 ±419.50 778.5 17 2210 
89 Percent 
(%) 
25.92 ±9.81 26.92 2.87 52.66 
 
 
The percentage row in table 4.10 does not represent the percentile equivalent of 
the absolute data as shown above, but is an independent parameter of a sample of 89 
subjects.  Ideally a CD4 percentage is used as the parameter to express CD4 count in 
children as opposed to the absolute CD4 count value but only 89 of the 128 subjects 
had results expressed as a percentage from the NHLS blood work-up as was found in 
the subjects‟ health records.   In table 4.10, the absolute and percentage mean reflects 
that the sample was generally „healthy‟ in terms of their immune status. 
 
Table 4.11: The summary statistics of the absolute CD4 count variable for each age category. 
ABSOLUTE CD4 COUNT ACROSS THE AGE CATEGORIES 
Age n Mean Std. Dev. Min Max 
6yrs 4 858.50 ±427.62 361 1263 
7yrs 13 923.77 ±581.23 17 2131 
8yrs 24 866.83 ±395.36 74 1588 









ABSOLUTE CD4 COUNT ACROSS THE AGE CATEGORIES 
Age n Mean Std. Dev. Min Max 
10yrs 16 687.50 ±351.20 75 1266 
11yrs 11 754.00 ±568.19 325 2210 
12 yrs 17 670.65 ±299.01 183 1130 
13yrs 13 584.54 ±245.46 20 1000 
 
 
Table 4.11 shows that across all age groups the mean CD4 count was above 
500 cell/mm
3
.  Since the normal absolute CD4 count is classified as being above 500 
cells/mm
3
, this would imply that all age groups had a satisfactorily functioning 
immune system, even though individually, not all subjects had a healthy functioning 
immune system.  Subjects in the 9 year old age group are perceived to be the healthiest 
group with the 13 year old subjects found to be within the lower range of a healthy 
functioning immune system.  
 
Table 4.12: The frequency of subjects in the different viral load categories 
VIRAL LOAD DISTRIBUTION 
Viral Load (copies/ml) 
Absolute Value 
Frequency  
(n = 125) 
Percent (%) 
<40 81 65 
>40 ≤ 1000 32 25 










The viral load data was categorized into 3 levels in table 4.12.  These categories 
were determined by the resultant effect that the HAART had on the virus in the blood.  
In category 1, if the viral load is < 40 copies/ml, it is classified as undetectable.  Table 
4.12 indicates that 65% of the sample fall into category 1 meaning that this portion of 
the sample is adequately responding to the HAART, which is currently effective in 
suppressing the virus in the blood.  If the viral load is > 1000 copies/ml, this is 
interpreted as virologic failure as the anti-retrovirals are ineffective at suppressing the 
viral load within the blood, which represents 10% of the sample.  Any value, expressed 
between 40 copies/ml and 1000 copies/ml indicates that there is a moderate viral load 
in the blood serum.  Twenty five percent (25%) of the sample was found to have a viral 
load between 40 copies/ml and 1000 copies/ml, which is not the desired goal.   
 
Table 4.13:  The summary statistics of the viral load variable across the complete sample of 
subjects. 
VIRAL LOAD  SUMMARY ( copies/ml) 
N Mean Std. Dev. Median Min Max 
125 7414.13 ±42038.5 0 0 368391 
 
Table 4.13 summarized the description of the viral load variable of 125 subjects 
as 3 subjects didn‟t have viral load data in their health records at the time of 
assessment.  As displayed in Table 4.13, the median and the mean differ significantly. 









figure in this study.  The median is the more accurate statistic as over 50% of the 
sample has an undetectable viral load (40 copies/ml).   
 
Table 4.14: The summary statistics of the viral load variable across the different age 
categories. 
VIRAL LOAD ACROSS THE AGE CATEGORIES 
Age n Mean Std. Dev. Median Min Max 
6 4 123.25 ±246.50 0 0 493 
7 12 70.83 ±155.54 0 0 513 
8 24 7269.50 ±33595.85 0 0 164849 
9 30 12563.37 ±67212.56 0 0 368391 
10 14 25670.57 ±64292.00 0 0 197829 
11 11 1099.73 ±2456.92 0 0 7628 
12  17 71.53 ±130.86 0 0 515 
13 13 104.77 ±353.56 0 0 1279 
  
Table 4.14 shows that the 8, 9 and 10 year olds have more significant viral load 
averages, well above the undetectable threshold, with only the 7 and 12 year olds 
having viral loads averages close to being undetectable.  The median across all age 
groups are zero indicating that 50% of all subjects in each age sample group had 
undetectable levels. This would then imply that in the 8 to 10 year age groups there 
were subjects with significantly high individual viral loads (<50% of the sample group) 
which elevated the viral load mean substantially.  Evidence for this is further supported 









group.  In this case, the median is a more accurate description of the viral load average 
in the different age group.  
4.2.2 Correlation Analysis 
 
Table 4.15: Numerical display of the associations between the variables expressed via 
Spearman‟s Correlation Co-efficient. 
RELATIONSHIP BETWEEN THE VARIABLES 
N VARIABLES SPEARMAN’S 
CORRELATION 
COEFFICIENTS (r) 
125 CD4 Count vs Viral Load -0.26674 
127 Treatment Duration vs CD4 Count 0.44084 
124 Treatment Duration vs Viral Load -0.14926 
89 Treatment Duration vs CD4 % 0.60420 
 
CD4 count versus Viral Load 
The co-efficient (r) that resulted when an association between the above 2 variables 
were compared was a negative correlation.  Also, with the r = 0.26, this indicated a 
poor or weak negative correlation as the value fell outside of the 0.6 to 1.0 strong 
correlation range. 
 
Treatment Duration versus CD4 Count 
When the association between these 2 variables were investigated a weak positive 









continued the CD4 count would increase which is what is believed, the correlation of r 
= 0.44 did not indicate a linear relationship.  
 
Treatment Duration versus Viral Load 
In the analysis of the trend between the above variables, a marginally weak negative 
correlation existed.  As treatment duration increased the viral load decreased which is 
an expectation of the HAART.  However, a precise linear relationship did not exist.  
 
Treatment Duration versus CD4 % 
As was expected a positive association between treatment duration and CD4 % existed.  
A further interpretation of the co-efficient was that the association between the 
variables was strong. The conclusion was then that a strong positive correlation 
existed between those variables. It must also be noted that of the 128 subjects of the  
sample that had available absolute CD4 counts, it was only 89 subjects that had 
available CD4 % data.   
 
4.3 DEM ANALYSIS PROFILE 
 
 
This section is divided into two sections where a more complex analysis of the 
data of phase 3 of the data collection process is presented.  In the first part, the 
researcher profiled the results of the DEM test.  The researcher examined the vertical 
times, horizontal times, DEM ratio and errors of the subjects, and compared it to the 









examined the prevalence of the behaviour types across the sample and focused the 
investigation for each age category.  Correlations and associations between the primary 
variable of behaviour type and other variables (viral load, CD4 count) were 
investigated to determine the existence of any trends to help answer the research 
question. 
 




Figure 4.2: The vertical times across the sample that fell within and outside of the DEM 
normative value. 
 
Figure 4.2 which illustrates the vertical times shows that almost 93% of the 
subjects had times that were outside of the DEM mean and standard deviation of the 
sample.  The absolute value was 119 subjects outside of the standard norm and 9 
subjects within the norm.  „Outside of the norm‟ refers to a combined time on subtest A 




























age-specified norms and differ for different age groups. Therefore, figure 4.2 is 
reflective of the overall performance of individual subjects across the full sample 
calculated against the mean and standard deviation (±SD) for each age category.  The 
±SD was always taken into consideration to assess the range of the mean. 
 
 
Figure 4.3: Mean vertical times for each age category against the DEM mean vertical time norm. 
Figure 4.3 is appropriately presented with the use of trend lines, the mean 
performance of subjects of different age categories from 6 years to 13 years together with 
the presentation of a data table for immediate reference.  The obvious interpretation from 
the graph is that the subjects‟mean performance were well below the DEM mean norm as is 
verifiable by the data table.   
6 7 8 9 10 11 12 13
Vert Time 120.28 115.11 101.78 86.8 81.43 68.71 72.14 71.94





















By further inspection of the ±SD of the DEM standard mean and the study mean, 
the findings were still consistent in that the ranges were still beyond each other. The study 
vertical times were significantly slower than the norm and in some cases the mean vertical 
times were more than twice the DEM mean norm times.  An inverse relationship between 






Figure 4.4: The percentage of individual horizontal times across the sample that fell within and 
outside of the DEM mean normative value for horizontal time. 
 
Figure 4.4 which illustrates the horizontal times expressed that  almost 92% of the 128 
subject pool had times that were outside of the DEM Mean and ±SD, with almost 8% 
within the DEM mean norm.  The absolute value was 118 subjects were outside of the 
Within DEM Mean Outside DEM Mean























standard norm and 10 subjects within the norm.  The results of the horizontal test 
(subtest C) almost mimic the performance on the vertical test.  As with the vertical test, 






Figure 4.5: Mean horizontal times for each age category is presented with the DEM horzontal time 
norm. 
 
Figure 4.5 demonstrates with the use of two trend lines joining the data points the 
subjects‟ mean performance at the different age categories against the DEM mean norm. 
The interpretation was that the resultant study means across the sample were below the 
norms as is evident with the presentation of a data table below the plot of figure 4.5.  The 
strategic use of a data table helped to verify the graph presented and showed that the 
average horizontal times were much slower across all the ages norms.  
6 7 8 9 10 11 12 13
Horizontal Time 214.27172.38132.04104.86 95.32 78.67 85.47 80.39



















A closer inspection of the standard deviations showed that the mean horizontal 
times for only the 9 year olds 104.86 (± 40.62) and 13 year olds 80.39 (± 35.98), marginally 
fell just within the standard deviation of the DEM norms for the 9 year olds 51.13 (± 13.30) 
and the 13 year olds 37.98 (± 7.23).  The usage of the word „marginally‟ in this context 
referred to the lower limit of the ±SD of the study sample overlapping the extreme upper 




Figure 4.6: A display of the percentage of subjects whose individual DEM ratio scores fell within 
































In figure 4.6, a comparison of the percentage of subjects‟ absolute ratio scores 
against the DEM mean ratio norm, it is evident that 45% of 128 subjects had ratios outside 
of the mean and ±SD in the full sample of subjects (Figure 4.6).  The absolute number of 
this being 57 subjects out of the 128.  This would mean that 71 subjects had their ratios 
within the DEM ratio norm.   
The 45% of subjects were further sub-divided for a more closer examination of the data to 
show that „Total Outside DEM Mean‟ was a combined expression of those that fell both 
above and below the standard mean ratios standard deviation.  An absolute number of 22 






Figure 4.7: Mean ratio for each age category is presented with the DEM mean ratio norm. 
 
 
6 7 8 9 10 11 12 13
Mean Ratio 1.93 1.54 1.31 1.22 1.18 1.17 1.2 1.11


















The mean ratio graph in figure 4.7 shows a different picture as compared to the 
mean vertical time graph and the mean horizontal time graph.  Even though the vertical 
times and horizontal times were much slower in the subjects as compared to the DEM 
norms, the mean ratios that are produced almost mimics the trend of the means for the 
DEM ratio.   
In 100% of the age categories, the study mean ratio and ±SD is within the DEM  ±SD for 





Figure 4.8: Representation of the percentage of subjects with error scores that fell within or outside 
of the DEM mean errors norm. 
 
Figure 4.8 presents the error parameter of the DEM test and exhibited that 66% 
(84) of subjects made errors during testing that were within the ±SD of the DEM mean 

































Figure 4.9: The  mean errors and the DEM norm mean errors across the different age groups. 
 
The Figure 4.9 above shows a higher mean error value in the younger age 
group and almost plateaus out from the 11 to 13 year olds range as is demonstrated by 
the trend line and supported by the data table.  The inverse relationship of age and error 
is apparent with the DEM norm as well as with the study sample results.  It is only in 
the age 7 category that for the 1
st
 time the study sample average for the error mean falls 




6 7 8 9 10 11 12 13
Mean Errors 19 7.31 8.42 7.47 7.25 3.27 3.53 3.15























Table 4.16: DEM norms compared against the findings in this study for the different DEM 
parameters  
 
RESULTS  SUMMATION  
n Parameter Mean Std. Dev. Min Max 
128 V. Time 87.85 ±29.19 34 177 
534 DEM Norm 44.17 ±8.39 - - 
128 H. Time 111.72 ±47.48 44.2 257 
534 DEM Norm 57.78 ±14.93 - - 
128 Ratio 1.27 ±0.34 0.56 2.89 
534 DEM Norm 1.28 ±0.22 - - 
128 Error 6.64 ±6.37 0 24 
534 DEM Norm 5.10 ±5.47 - - 
 
Table 4.16 is a comprehensive display of the means and standard deviations of 
each of the 4 test parameters for the full sample in the study.  The researcher inserted 
the DEM normative values for the purposes of comparison only.   
The values for each parameter are not of any important significance as each age 
category has its own independent mean and ±SD.  The purpose of this presentation of 
combining and averaging the data across the sample to produce one mean and ±SD 
was to demonstrate the overall differences in performance of the sample against the 
DEM standard norms for the reader to appreciate.  The DEM test used a sample of 534 

















Figure 4.10: Percentage of subjects classified into the different behaviour types from 1 – 5. 
 
As is displayed in figure 4.10, there are 5 behaviour types of which type one to 
four are the standard behaviour types (Table 3.1)  as classified by the DEM test and type 5 
represents the unclassified type (Table 3.1).  The colours representing the different 
behaviour types will remain consistent through out this chapter for easier and quicker 
identification for the reader‟s convenience. 
Behaviour type 3 was the most prevalent in the study sample making up 53% (68) 
of subjects and type 2 was the least prevalent in the sample making up only 3% (4) of 
subjects.  A surprising 14% (18) of subjects fell into an unspecified category of behaviour 
types.  The distinct characteristic of this type 5 is the low ratio.  Of the 18 subjects in this 
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type 3 and type 4 but with a low ratio outside of the norm for that subject‟s age.  The 







Figure 4.11a-d: A presentation of the behaviour type trends in the age groups 6 – 9 years old. a) 
Behaviour type trend in 6year olds.  b) Behaviour type trend in 7 year olds. c) Behaviour type trend 
in 8 year olds. d)  Behaviour type trends in 9 year olds. 
 
 
The above four pie charts represent the prevalence of the different behaviour types 
in four age categories.   A display of the next four age categories will be presented after 
this discussion.   The reason the researcher opted to present four pie charts of the different 
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immediate visual comparison and assessment of the data purely for the convenience of the 
reader.   
In pie chart (a) displaying the behaviour trends in 6 year old subjects, the only 
behaviour types that are present is behaviour type 2 and behaviour type 3.  The sample size 
(n) in this age category is only four which then means that one of the four exhibited pure 
oculomotor dysfunction. 
 
In pie charts (b) – (d), the behaviour type 2 once again featured as the smallest 
percentage of the pool but yet again still represented only one subject.  The reason the 
percentage of behaviour type 2 decreased with age is because the sample pool in the 
different age categories increased from n = 13 in 7 year olds, n= 24 in 8 year olds and n= 30 
in 9 year olds.  Consistently, it was noted that behaviour type 3 made up no less than 57% of 
the sample in the different age categories.  Behaviour type 5 (light blue) featured at the age 


















Figure 4.12a-d: A presentation of the behaviour type trends in the age groups 10 – 13 years old. a) 
Behaviour type trend in 10 year olds.  b) Behaviour type trend in 11 year olds. c) Behaviour type 
trend in 12 year olds. d)  Behaviour type trends in 13 year olds. 
 
Figure 4.12 represents age groups from 10 years to 13 years.  The immediate 
impression is that behaviour type 2 (red) is absent from these four age pools.  
The size of the sample in the above age categories are as follows (refer to Table 4.3): 
10 year olds n = 16 
11 year olds n = 11 
12 year olds n = 17 
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Throughout these four age categories and the previous four age categories behaviour type 4 
(purple) has never exceeded 41% or an absolute number of 7 subjects in any of the eight age 
categories and it has the highest prevalence in the 12 year old age category. 
Behaviour type 1 (dark blue) appears to increase in prevelance consistently as the subject 
samples got older from the 9 year olds to the 13 year olds. 
Behaviour type 5 (light blue) never seemed to exceed the quarter mark of the sample pool in 




Figure 4.13: A presentation of the prevalences of the different behaviour types in the three virologic 












< 40 > 40 < 1000 > 1000
Type 5 13 3 2
Type 4 18 6 2
Type 3 43 20 4
Type 2 3 1 0














In Figure 4.13 each cylinder comprised of the different types of behaviour that 
is prevalent in the three virologic categories. The data table was presented beneath the 
graph to effectively express the data comprehensively for easy interpretation.   
 
Subjects with an undetectable viral load are most prevalent of the three 
virologic categories as was previously presented, hence a much taller cylinder is seen 
in Figure 4.13 in the first of the viral load categories with a shortest cylinder in the 
virologic failure category.  This category represented 12 subjects as can be identified 
with the use of the data table placed below the graph. 
 
Behaviour type 3 (green) is the most prevalent type in all three virologic 
categories.  Behaviour type 2 (red) is the least prevalent and is absent in the virologic 
failure category.  The prevalence the individual behaviour types from 2 to 5 decreased 
as the viral load categories increased from undetectable levels to virologic failure 
(Figure 4.13). Behaviour type 1 ( dark blue) is the only type that had the same number 











Figure 4.14: A presentation of the prevalences of the different behaviour types in the three 
immunologic status categories of the sample. 
 
In Figure 4.14, each cylinder comprises of the different types of behaviour but 
that which is prevalent in three immunologic categories.  The data table was presented 
beneath the graph to present a snapshot of the raw data for each behaviour type of the 
three categories for immediate referral, assessment and interpretation.   
 
As was previously demonstrated in Table 4.9, subjects with minimal or no 
immune suppression were in the category with the highest number of subjects that 












< 200 > 200 < 500 > 500
Type 5 3 3 12
Type 4 0 4 24
Type 3 2 13 53
Type 2 0 0 4














cylinder and confirmation of this is by adding the total behaviour types in the last 
column on the data table under the cylinder that graphically represents this data.  
 
From the Figure 4.14 it is once again observed that behaviour type 3 (green) is 
most prevalent in category 2 (>200<500) and category 3 (>500).  Behaviour type 5 is most 
prevalent in catergory 1 and 2 (<200) which describes the group with severe immune 
suppression.  Behaviour type 2 is absent in categories 1 and 2 and only features in subjects 
in the „healthy‟ 3rd category making up all 4 of the 128 subjects found with this behaviour 
type.  Subjects with behaviour type 4 occur in category 2 and 3 having the 2
nd
 highest 
prevalence in both the categories but is absent from category 1. 
 
 
4.3.3 Probability  
 
Behaviour Types and Viral Load  
In the analysis between the viral load and the behaviour types a 3 x 5 table Chi 
Square analysis was performed. The viral load was categorised into 3 categories as was 
described in Table 4.12 and compared to the 5 behaviour types. Ideally a 2 x 2 table 
would be most appropriate for this type of analysis.  Results of the test indicated poor 
reliability as 53% of the cells had  expected counts that were less then 5. 
Alternatively the Fisher‟s Exact test was conducted to determine probability.  
With n = 125, p >0.05. precise p value = 0.2.  This larger p value indicated that there is 
weak evidence against the rejection of a null hypothesis, hence the null hypothesis is 
accepted.  This indicated that there was no statistically significant difference between 










subjects that had displayed type 2 behaviours, 3 of them were in the category of 
undetect viral load contrary to what was predicted. 
 
Behaviour Types and the CD4 Count 
 A Chi Square test was performed using 3 x 5 tables where the CD4 count was 
compared to the different categories of behaviour types.  The CD4 count was grouped 
into the categories as described in Table 4.9.  The results showed that 67% of the cells 
had counts less than 5 so the use of the Chi square test in this case was not valid.  The 
Fisher‟s Exact test revealed with n = 128, p > 0.05.  Precise p value = 0.17.  This p 
value indicated that there is weak evidence against the rejection of a null hypothesis.  
This indicated no statistical significance between the categories of the behaviour types 
and the CD4 count variables. However, of the 4 subjects exhibiting type 2 behaviours 
all fell into the category of minimal immune suppression as was with the viral load, 
contrary to what was predicted. 
 
4.4  SUMMARY OF RESULTS 
 
4.4.1 Demographic Profile:- 
 Figure 4.1:  54% of subjects were accessed from hospital sites with 46% of 
subjects accessed from clinics. 
 18% of subjects were seen in the Xariep District and 82% of subjects from the 
Motheo District. 
 Table 4.1: 48% male subjects and 52% female subjects 









 Table 4.3: 23% of subjects were 9 years 11 months as the most prevalent mean 
age and 3% were 6 years and 11 months as the least prevalent mean age. 
 
4.4.2 Clinical Profile:- 
 Table 4.4: Median time period from birth until the HIV status is confirmed was 
6 years and 1 month. 
 Table 4.5: Median time period from diagnosis of HIV to the commencement of 
HAART was 9 months. 
 Table 4.6: Median time period from birth until HAART was initiated was 7 
years. 
 Table 4.7: Median duration of subjects on HAART was 2 year and 10 months. 
 Table 4.8: 6 year old subjects were on HAART for the longest period of a 
mean of 44.67 months.  The 12 year old subjects were on HAART for the 
shorted time with a mean of 29.53 months. 
 Table 4.9: 78% of subjects had CD4 counts ≥ 500 cells/mm3. 6% of subjects 
had severe immune suppression. 
 Table 4.10: Median CD4 count of the sample was 778.5 cells/mm3. 
 Table 4.11: Highest mean CD4 count was in the 9 year old group and the 
lowest mean CD4 count was in the 13 year old group. 
 Table 4.12: 65% of subjects had an undetectable viral load and 10% of subjects 
were in the virologic failure category. 










 Table 4.14: Median viral load across all age groups were 0 (<40 undetectable 
level). 
 Table 4.15: CD4 count versus Viral Load – weak negative correlation. 
Treatment Duration versus CD4 Count – weak positive correlation. 
Treatment Duration versus Viral Load – marginally weak negative 
correlation. 
Treatment Duration versus CD4 % – strong positive correlation. 
 
4.4.3 DEM Analysis Profile:- 
 Fig.4.2: 93% of the subjects had vertical times that were outside of the DEM 
mean and standard deviation of the sample. 
 Fig.4.3: 100% of the mean vertical times per age group were higher than the 
DEM age-specific mean and standard deviation. 
 Fig.4.4: 92% of subjects had horizontal times that were outside of the DEM 
mean and standard deviation of the sample. 
 Fig.4.5: 100% of the mean horizontal times per age group were higher than the 
DEM age-specific mean and standard deviation. 
 Fig.4.6: 45% of subjects have ratio scores outside of the DEM mean with 55% 
within the specified mean norm. 
 Fig.4.7: Subjects in 7 of the 8 age groups had ratios within the DEM age 
specified norms except for subjects in the 6 year old category which had results 









 Fig.4.8: 66% of subjects had errors that were within the DEM mean and 
standard deviation with 34% outside of the mean. 
 Fig.4.9: Subjects in 7 of the 8 age groups had their age-specified means of error 
above the expected DEM norm expect for the subjects in the 7 year old 
category whom had errors below/less than the DEM age-specified norm. 
 Table 4.16: DEM standardised norm values were determined with a sample of 
534 subjects.  Vertical and horizontal times were well above the DEM 
standardized norms. Errors and ratio was with the DEM standard norm values  
 Fig.4.10: The highest prevalence of behaviour types of the sample was 
behaviour type 3 with 53% with type 2 behaviours (saccadic dysfunction) with 
the lowest prevalence of 3%. 
 Fig.4.11: In the different age categories, behaviour type 3 was the most 
prevalent. Subjects with type 2 behaviours where present in age group 6 years, 
7 years, 8 years and 9 years.  The prevalence decreased with increasing age 
group. 
 Fig.4.12: Subjects from 10 to 13 years showed no type 2 behaviours with an 
increase in type 1 behaviours (normal) with increasing age. 
 Fig.4.13: Subjects with undetectable viral loads had the highest prevalence of 
all behaviour types except for the virologic failure category, which matched the 
undetectable viral load category for type 1 behaviours. 
Of the subjects displaying type 2 behaviours, 3 were in the undetectable viral 









 Fig.4.14: Subjects in the „no/minimal suppression‟ category of the CD4 count 
indicator, had the highest prevalence of all behaviour types. 
All subjects displaying type 2 behaviours had CD4 counts in the „minimal to no 
immune suppression‟ category. 
The computation of the p value in assessing statistical significance indicated 
that in evaluating the relationship between the behaviour types and the viral 
load and CD4 count there was not a statistically significant difference between 












DISCUSSION, LIMITATIONS, CONCLUSION, 




5.1.1  Demographic Profile 
 
The demographics of HIV positive children on treatment in this study with 
reference to the sample pool at each site is not representative of the geographic 
distribution of HIV positive children in the Free State. Due to the administrative 
systems at Botshabelo Hospital and J.S Moroka Hospital, patients had been more 
accessible at these sites than at the other sites hence a larger pool of subjects was 
selected from these two locations.  This however did not bias the sample in any manner 
as the HIV/AIDS  treatment and management prrogram for paediatrics in the province 
is consistent through all treatment centres and regulated by the Free State Department 
of Health. 
 
The gender distribution of the sample closely mimics the true proportion of 
male and female children in the Free State Province.  In the Free State, we have 
approximately 50.20% male and 49.70% females in the age category from 5 to 15 year 










With almost a quarter (23%) of the sample being 9 year old subjects, only 4 
subjects were from the 6 to 6 years and 11 month old category.  The reason for a small 
sample of 6 year old children was because they were largely illiterate and moderately 
familiar with verbalizing numbers and these factors required them to be excluded 
according to the specified exclusion criteria.   
 
None of the 128 subjects used English as their home language.  The home 
languages of the subjects were Sotho, Afrikaans and Tswana.  Subjects from the 
Xariep district in the South-Western Free State used Afrikaans and Sotho as their home 
language, whereas subjects from the Motheo district used Sotho as their home 
language.  Subjects from the Thabanchu area in the eastern region of the Motheo 
district, who attended the J. S Moroka Hospital, predominately used Tswana as their 
home language along with Sotho.  However, English was used in school along with 
Afrikaans, Sotho and Tswana during the teaching process and informal communication 
outside of the classroom.    
 
5.1.2  Clinical Profile 
 
Even though it is noted in the health records that the mode of infection amongst 
all subjects in the sample is from mother-to-child-transmission, there is no guarantee 
that horizontal modes of infection are not possibilities.  Such modes of transmission 
include sexual abuse, iatrogenic transmission from hospitals or clinics and receiving of 
breast milk from HIV positive mothers who are not the biological mothers (Brody et al, 










When a child is born from a mother that is HIV positive, that child is classified 
as “HIV-exposed” as the child will be carrying HIV antibodies from the mother due to 
trans-placental transmission.  An antibody test (HIV ELISA and HIV Rapid Test) in an 
infant can only be done after 18 months of birth to confirm the diagnosis of HIV 
infection (RSA. KZNDOH, 2010).  The reason for this is that a mother‟s HIV 
antibodies are still found in the infant up to 18 months of age.  Alternatively, a PCR 
test is done to detect viral genetic material in a child at any age without any waiting 
period (Nutall, 2012). 
 
As shown in Table 4.4, the median value of 6 years was the average waiting 
period for subjects in this study to be confirmed as HIV-infected even though this 
could have been done from 18 months of age with an antibody test. Among other 
factors, there are patient-centred reasons to why the average time of diagnosis was not 
sooner as one would have hoped for.  Examples of these factors could include poor 
education, non-compliance with appointments, lack of urgency with collection of 
results and denial of circumstances, all of which play a role in the delay of 
confirmation of the diagnosis. 
 
The waiting period for the initiation of treatment showed a median of 9 months 
with a maximum waiting period of 10 years and 7 months (Table 4.5).  Possible 









1. Not all HIV-infected children were eligible to be on HAART according to the 
previous treatment guidelines for HAART initiation in children. 
2. Inadequate access to treatment medication for children.  
3. Poor training of health care personnel and knowledge on the drug regimens for 
children in the beginning stages of the roll out. 
4. Care-givers not given the results of the diagnosis timeously 
5. Roll out of ARVs commenced only in 2004 with slow focus on children and 
preparation (Michaels et al, 2006). 
 
From an evaluation of 127 subjects, Table 4.6 expressed the equal median and 
mean times for the time period from birth until the start of HAART, which was 7 
years.  The interpretation of this is that if children who are born to HIV positive 
mothers are eventually diagnosed with HIV infection and are put on HAART, this 
process will usually span a period of approximately 7 years.  A study with a larger 
cohort should confirm if this is the current situation for a population of HIV/AIDS 
children in South Africa.  The 2004 roll out of ARVs in South Africa may have 
significantly contributed to the long waiting period for subjects in this study.  This 
delayed initiation has undesirable consequences, which may reduce the length of 
survival, affect morbidity and mortality rate and further influence the incidence of 
neurodevelopmental impairment.  Hoffmann et al (2013) showed that the long-term 
clinical outcome would be better if initiation was started earlier at higher CD4 counts 
and lower baseline viral loads.  Alternatively, McCombe et al (2013) stated that 









symptomatic HAND.  This would be a consequence of the long-standing presence of 
HIV in the sanctuary site of the CNS.  
 
As described in Table 4.7, the maximum treatment duration of subjects in this 
study was 7 years and 8 months which can be explained by the roll out of ARVs 
commencing in 2004 and not prior to this date.  Therefore, neither a child, nor an adult 
in the public health sector would have had access to HAART for more than 8 years in 
South Africa.  In this study, the eldest subjects were 13 years and 11 months, born in 
1999.  When the roll out of ARVs commenced only in 2004 at a time when children 
were not prioritised for treatment, this lead to the understanding that the subjects of this 
study that were born from 1999 to 2003 did not receive treatment during these years 
regardless of whether they had satisfied the criteria.  This situation had resulted in the 
waiting period for initiation of HAART being skewed to a lengthier time period for the 
subjects of this study. 
 
The duration of HAART for subjects within the nine age categories ranging 
from 6 years to 13 years (Table 4.8) showed that the younger subjects had been on 
HAART for a longer time period that the older subjects.  This evidence contributed to 
our understanding that the older children were not promptly started on treatment 
compared to the younger subjects.  This also was a good indication that improvements 
have been made in the public health system where children are started on treatment 










Analysis of the CD4 count results revealed that the subjects in this sample are 
largely “healthy”.  This interpretation was derived from the fact that in Table 4.9, 78% 
of the subjects had CD4 counts above 500cells/mm
3
, implying that their immune 
systems were adequately able to sustain their health.  This was probably a result of the 
HAART that is sustaining their immunity to optimal levels.  The average CD4 count of 
the whole sample is above 500 cells/mm
3 
as is seen in Table 4.10, confirming that the 
subjects in this study are responding positively to the HAART in maintaining a healthy 
immune system. 
 
With a closer inspection of the mean CD4 count in each age group (Table 
4.11),  stronger immune systems were seen in subjects from 6 to 9 years old.  Subjects 
with lower CD4 counts were seen in the 10 to 13 year old groups but still within the 
„healthy‟ range.  No age group averaged CD4 counts of below 500 cells/mm
3
 even 
though subjects in the 13 year old age group had the lowest mean.  The highest CD4 
count and the longest duration of treatment was noticed in the younger age groups with 
the older subjects having shorter treatment durations and CD4 counts in the low-
normal range.  
 
 A correlation analysis was conducted between treatment duration and CD4 
count (Table 4.15) and it showed that a positive correlation did exist between those 
variables indicating that the CD4 count increased with longer sustained period of 
adherence to treatment, however it was not a strong association as the relationship 









contribute in slowing the rate of increase in the CD4 count and may even blunt a full 
recovery to satisfactory elevated levels (Tesiorowski, 2001). 
 
With the assessment of the subjects viral load in Table 4.12, 65% of the 
subjects had  undetectable viral loads, which could be attributed to the HAART 
controlling viral replication in the blood.  In all age categories, the median for the viral 
load was undetectable which meant that 50% or more of the subjects in each age group 
had undetectable viral loads as is demonstrated in Table 4.14.  Expression of the viral 
load as log units would have been ideal and more valid as the absolute values of the 
viral load ranged from double digits to millions of copies which made data analysis 
challenging.  
  
With only approximately 35% of subjects having detectable viral loads, of 
which 10% had virologic failure while on HAART, this implied that the overall subject 
pool had adequate viral suppression in the blood due to HAART.  The reasons for 
virologic failure in subjects on HAART could range from poor treatment adherence to 
failure of the initial drug regimen resulting in viral rebounding due to activation of 
latent viral reservoirs.  Poor adherences in children are due to many social and 
psychosocial reasons, which make compliance more difficult with children than with 
adults.  A study by Haberer and Mellins (2009) that looked at paediatric adherence 
found that child characteristics differ from caregiver characteristics with non-
adherence to treatment resulting in failure of HAART.  A child may skip medication if 









lifelong.  Psychosocial factors of depression and denial of condition may occur with 
maturity into adolescence.  Poor education of caregivers or collapse of the child-
caregiver relationship may also be contributing factors.  Furthermore, a Romanian 
study found that adherence under the care of non-related caregivers is very poor as 
there is a lack of emotional attachment to the HIV-infected child (Cupsa et al, 2000). 
  
Theoretically, one would expect to see a strong negative correlation between 
CD4 count and viral load.  However, in evaluating the correlation between these two 
critical biomarkers (Table 4.15), a negative but weak correlation was found in this 
study.  This finding is also supported by earlier studies showing a modest to poor 
correlation between these two biomarkers (Jurriaans et al, 1994; Mellors et al, 1996; 
Mofenson et al, 1997) which is blamed on the insidious behaviour of the virus.  
  
A correlation analysis between treatment duration and viral load shared a 
negative trend with a very weak correlation.  This is evident from Table 4.14, where 
erroneously high viral loads were found in certain age categories preventing a non-
linear negative trend.  This could possibly be due to changes in the social environment 
of the subjects which affected the steady success of the HAART in suppressing the 
viral replication in the body and as well as interruption in treatment which could have 
blunted a sustained suppression of viral replication.  Activation of the virus from its 
latent state in different sanctuary sites for whatever reason could have lead to the 









interrupted or that there was poor treatment compliance in subjects, such information 
would reluctantly be divulged by the care-giver. 
 
5.1.3 DEM Analysis Profile 
The vertical (Figure 4.3) and horizontal (Figure 4.5) times were distinctly 
slower across all age groups in this sample when compared to the specified DEM 
norm.  However, the mean ratios (Figure 4.7) and the mean errors (Figure 4.9) were 
within the specified norms.  There are many intrinsic and extrinsic causative factors 
that may have contributed to the overall slower times.  Blanchette et al (2002) 
indicated that in specific areas like information processing speed, there may be subtle 
deficiencies within this population, which is a plausible cause for the subnormal rates 
in both vertical and horizontal tests.  Puthanakit et al (2010) studied neurocognitive 
function in Thai children aged 6 to 12 years using the Welscher Intelligence Scale for 
Children III (WISC III) and showed that neurocognitive functioning in HIV-infected 
children on HAART are lower than that of non-infected children.   
 
 A study by Martin et al (2006) concluded that HIV-infected children on 
HAART functioned within normal limits in certain neuropsychological tests, however, 
differences in performances did exist between subjects with varying levels of brain 
neuroimaging abnormalities.  This study emphasised the importance of incorporating 










Other intrinsic factors relate to the neuropathogenesis of the disease and how 
effective HAART is in controlling CNS viral load, which this study had limited insight 
into due to inadequate research in these areas of paediatric HIV neuropathogenesis 
within the African population.  The reversal of neuropathologic deficits in infected 
children on HAART still remains unclear as studies by Chirboga et al (2005) and 
Lindsey et al (2007) showed modest improvement whereas a study by Nozyce et al 
(2006) showed persistent mild behavioural and cognitive impairment in the presence of 
HAART.  
 
Variations in HIV subtypes and their neuropathogenesis may also be a factor 
that influenced the cognitive ability in HIV infected children as small genetic variants 
between HIV strain subtypes have different neurotoxic potential as discussed in a study 
by Strain et al (2005) and rates of dementia may also be different (Sacktor et al, 2009).  
As there are different HIV subtypes found in different regions of the world (Levy, 
2009), clinical guidelines and management relating to neurodevelopmental 
impairments in children in Africa must not be dependent on results done in the United 
States and Europe.  These regions have different HIV subtypes that are not 
characteristic to what is found in Southern Africa (Levy, 2009).  Health professionals 
should not only be aware of the type of HIV strain that their patients have but of the 
clade or subtype they have contracted.  Even though the treatment regimens remain the 
same regardless of strain and subtype, the knowledge of different subtypes which have 
different virulence in terms of neurcognitive impairment pathogenicity (Sacktor et al, 










Extrinsic factors which may have contributed to a sub-standard performance 
demonstrated by the DEM test results, relate to the social environment and educational 
support that may have influenced the neurodevelopment and cognitive potential of the 
subjects.  Most of the subjects in this study are from rural and semi rural areas that 
attend school in those areas and access the public health services.  A South African 
study by Smith et al (2008) using a battery of standardized cognitive tests that 
described verbal and non-verbal intelligence scores, showed that HIV-infected children 
on HAART were much lower than those of non-infected children.  The study further 
indicated that neurocognitive development in HIV/AIDS children are influenced by 
their socio-economic factors, poor household educational stimulation and nutritional 
profile.   
 
The DEM test has standardised norms developed with American children who 
are English-speaking learners.  The subjects in this study are all non-English speaking 
learners and all were from poor socio-economic backgrounds.  Earlier, Fernandez-
Velazquez and Fernandez-Fidalgo (1995) from their study on Spanish-speaking norms 
concluded that the DEM is a reliable tool independent of language differences.  
However, Pang, Lam and Woo (2010b) proposed DEM norms for Cantonese-speaking 
children and cautioned that population-specific norms must be established to minimise 
bias caused by factors such as language and education.  Bapista et al (2011) described 
in their study using the DEM test in Portugese-speaking children that language, 









The implications of the conclusions drawn from the previous studies mentioned above 
does entertain the possibility that the findings in this current studies may possibly have 
been influenced by similar factors as was experienced in those studies in their different 
populations, or possibly not.   
 
Behaviour type 3 was distinctly the most prevalent in the study (Figure 4.10) 
showing that RAN was a significant problem that was revealed in this population with 
eye movement dysfunction manifesting in an insignificant proportion of the subjects. 
Deficient automaticity skills may or may not be due to HIV, however, as described in 
this study, it does exist within the population of school-aged children with HIV/AIDS 
on HAART.  The causes for the automaticity problems could be multifactorial ranging 
from pathological to socio-economic factors as was with the overall performance in the 
vertical and horizontal scores.  
When behaviour type prevalences were compared to the age variable (Figure 
4.11), an apparent age-dependant trend was visible.  Subjects with eye movement 
abnormalities were most prevalent in the youngest age group but reduced as age 
increased and was absent from 10 years onwards (Figure 4.12).  Normal DEM 
performances (type 1 behaviours) were absent in the 6 year old and 9 year old age 
groups but increased significantly from 10 years upwards with the highest prevalence 
in the 13 year old age group.  Deficiencies in automaticity skills or RAN, which were 
the highest with the 6 and 7 year olds reduced significantly in the 12 and 13 year old 
groups showing that there is a trend towards normality as the subjects aged as is shown 










The subjects in the 6, 7 and 8 year old age groups who averaged the longest 
duration on HAART had high prevalences of type 2 and type 3 behaviours.  The older 
subjects in the 11, 12 and 13 year old age groups averaged much lower treatment 
durations but had better performances on the DEM. The assumption that poor 
performances on the DEM test is linked to treatment duration or the effect of a longer 
duration on HAART were beyond the scope of this study but does warrant further 
investigation.   
 
A significantly large portion of the sample had undetectable viral loads (65%) 
(Figure 4.13) and higher CD4 counts with minimal immunosuppression (78%) 
(Figure 4.14).  Due to the high prevalence of subjects in these „healthy‟ categories, all 
five behaviour types were most prevalent in these two categories rendering any viable 
comparison of different behaviour types to different viral load and CD4 count levels, 
inconclusive.  This finding challenged the notion that subjects with higher viral loads 
would perform poorer on the DEM test and be symptomatic of eye movement 
problems.  It was found that no subject with type 2 behaviours where found in the 
category with VL > 1000 copies/mm
3 
and 4 of the 12 subjects in this viral load 
category had normal DEM performances (Type 1 behaviour).  A similar result was 
demonstrated when comparing CD4 counts to different behaviour types as was with 
the comparison done with viral load.  All behaviour types were significantly higher in 











 Subjects classified as having saccadic eye movement problems (Type 2) were not 
severely immunocompromised, hence no link between their immune and virologic 
status to their diagnosis based on the DEM was established.  This finding further did 
not support the expectation that unhealthy and severely immunocompromised subjects 
would have significantly lower performance rates on the DEM.  It also did not support 
the preconceived notion that there would be a high prevalence of behaviour type 2 
subjects in the lower immunity categories.  There was no statistically significant 
difference between the different behaviour types and the CD4 count and viral load 
categories. 
 
There were no reliable indications of immunologic and virologic biomarkers 
influencing the performance on the DEM test without a convincing relationship to eye 
movement problems in this population.  A relationship between the performances on 
the DEM test and the disease biomarkers remains unlinked.  The only finding that 
supports a possible relationship with the DEM performance was that of the age of the 
subjects with the behaviour type trends.  There was a progressive increase in the 
normal scoring in the DEM test (Type 1) with the ageing of the subjects however, it 
was still below the established norms.   
 
The DEM test showed different behaviour types in the sample population but it 
failed to show that those with poorly sustained immune systems and high viral burdens 
had oculomotor dysfunctions.  The obvious finding that was evident in the study was 









were the highest across all age groups but its prevalence decreased with ageing 
children.  Furthermore, children with the longest duration on HAART had higher 
automaticity and eye movement problems but were in the younger age groups.  There 
was no relationship established between poor automaticity skills and disease 
parameters of CD4 count and viral load in this study but relationships between these 
parameters to other neurocognitive functions by other neuropsychological tests have 
been demonstrated (Martin et al, 2006; Smith, Smirnoptopoulos and Rushing, 2008). 
 
Efficient automaticity requires good cognitive ability as the DEM test is a 
visual-verbal test.  The essence of the DEM test is that it is patient-reliant, hence it is a 
subjective instrument.  Cognitive functions such as visual memory, visual 
discrimination, visual information processing, processing speed and verbalisation are 
important components for performing the DEM Test and these are cognitive-dependant 
skills.  Automaticity problems may a predictor or risk factor of neurocognitive 
impairment as it is cognitive-dependent.  Other neurocognitive testing would need to 
be conducted to confirm if the findings of the DEM test is a reliable indicator of 
neurocognitive impairment, which is known to occur in this population.  The DEM test 
has value as a screening tool in a subtest of neuropsychological tests beyond its 
description as an eye movement test as the dependency of this test is heavily reliant on 
a series of cognitive skills.  A study by Ayton et al (2009) concluded the DEM failed to 
correlate well with other objective measures of saccadic eye movements to be a 









reading and academic delays due to its reliance on cognitive functions such as 
verbalisation and information processing speed. 
 
Strong immunity and low viral load as detected in the blood are not reliable 
indicators that the CNS is unaffected.  Studies by Cysique, Maruff and Brew (2004) 
and Dore et al (2003) showed that since subjects have been started on HAART earlier, 
the incidence of HAD reduced but the increase in the prevalence of HAND occurred 
with increased survival due to HAART.  A study by Ruel et al (2012) showed that HIV 
infected children with good CD4 counts, who were not eligible for HAART, 
manifested with neurocognitive and motor deficits which then questioned the WHO 
threshold guideline for eligibility for treatment.  If eye movement dysfunction is not 
characteristic in this population of HIV-infected school-aged children on HAART but 
deficiency in RAN is evident it may be plausible that automaticity skill may be 
indicator of neurocognitive impairment or neurodevelopmental delays.  
 
The DEM in essence still has validity and reliability as a screening tool in 
clinical practice as its function extends beyond the detection of eye movement 
dysfunctions and should be used in parallel with other tests of neurocognitive function 
that are used by optometrists.  Screening of neurocognitive function in a school-aged 
patient is important for the monitoring of their neurodevelopment and for optimal 
multi-sensory learning in the HIV/AIDS population of school-aged children and even 
those unaffected by HIV/AIDS.  The question arises as to whether the automaticity 









different population or if it‟s related to HIV/AIDS with the possible existence of 
neurocognitive impairments in the current population of subjects.  This study supports 
the suggestion by Martin et al (2006) in emphasising that neuropsychological testing 
needed to be done in all HIV-infected children regardless of their treatment status.  
Optometrists need to play a more significant role in screening and referring such 
children as part of a universal health care approach beyond just the attention to primary 




















5.2  LIMITATIONS 
Below are the descriptions of the limitations of this study that was identified during 
and after the study. 
 
 The incompleteness of subjects‟ health records at certain state health facilities 
posed a challenge, which resulted in a significant number of candidates being 
excluded from the study.  Pre-existing neurological or neurocognitive 
disabilities, previous hospitalisation details and the time frame of such were 
unclear in the documentation.  Not all subjects had absolute CD4 counts and 
CD4 percentage calculations as well as absolute viral load and log unit 
expressions, which would have made data analysis of these parameters easier 
and simpler. 
  
 A pilot study should have been conducted which would have identified the 
challenges described above more efficiently.   
 
 All subjects in this study were presumed to have contracted HIV through 
vertical mother-to-child transmission.  Records did not indicate if MTCT was 
the mode of transmission or if contraction of HIV occurred through different 
modes beyond the infancy age.  However, the mode of transmission of all 
subjects was accepted to be MTCT during the neonatal age of the subjects for 










The current caregivers of the subjects were not necessarily the biological 
mother as most biological mothers were deceased. Accurate and detailed case 
histories of the subjects were therefore limited. 
 
 The health facilities had different procedural systems as to when subjects are to 
present themselves to the clinics which affected the sample size and rate at 
which subjects were acquired using the convenient sample selection process for 
this study.  The restricted sample size could thus limit the ability to generalise 
findings in this study. 
 
 There were a limited number of 6 year old subjects in this study due to poor 
numeracy skills hence the 6 year old age category was comparably small to the 
other age categories. 
 
 None of the subjects had any neuropsychological or neurodevelopmental 
testing done to assess the cognitive state of the subjects prior to this study. This 
meant that the neurocognitive functioning of the HIV-infected subjects before 
and after HAART was unknown.  
 
 Other variables that could have influenced the outcome of the study where 
social, socio-economic and educational backgrounds, none of which were 










 As this study was a descriptive and not an analytical design, it limited a 






























5.3  CONCLUSION 
This section states the conclusions drawn from the research enquiry of this study.  
 
In answering the research question:- 
I. Immunologic and virologic statuses in children with HIV/AIDS on 
HAART cannot be predicted from abnormal saccadic eye movements.  
 
In addressing the primary objectives of the study:- 
I. The prevalence of saccadic eye movement abnormalities in HIV 
positive paediatric subjects on HAART was very low. 
II. There was no relationship between the saccadic eye movement 
abnormalities and the immunologic and virologic biomarkers in 
children with HIV/AIDS. 
 
In the addressing the supportive investigations of this study:- 
I. There was a weak negative correlation between the immunologic and 
virologic biomarkers. 
II. The prevalence of eye movement abnormalities decreased from 6 years 
old to 9 years old and thereafter was absent in the older age categories. 











Other conclusions drawn from this study:- 
I. A clinically significant number of subjects from this specific population 
manifested with problems in automaticity skills. 
II. Performance times in all 3 subtests of the DEM was significantly 
reduced in all age groups according to the specified norms. 
 





















5.4  RECOMMENDATIONS AND SUMMARY 
The limitations of this study could be addressed by the following recommendations. 
Considerations for future studies are further proposed below. 
 New norms for a DEM test based on non-English speaking children in a South 
African population should be established. South Africa is a nation of multiple 
home languages with diverse cultural backgrounds, it should ideally have 
standardised norms developed from and for its own population for adoption.  
This could strengthen the reliability and validity of the results that infer deficits 
in eye movement and automaticity problems for the South African population.   
 
 Since social and educational factors influence performance on neurocognitive 
and neuropsychological tests, a study using the DEM test to compare children 
of different social, economic and educational backgrounds beyond language 
differences, should be undertaken. 
 
 The DEM test can be used or tested as part of a battery of neuropsychological 
tests in school-aged children with vertically acquired HIV to determine if its 
results are consistent with other neuropsychological tests. 
 
 A similar descriptive study with an analytical design should be done by 
comparing the cognitive ability in performing the DEM test amongst subjects 









HAART and an HIV-uninfected control group.  A control may be valuable to 
determine if HIV has a negative effect on a child‟s eye movements and 
neurocognitive development that is manifested through the DEM test.  
 
 To enhance the accuracy of eye movement testing using the DEM test, 
instructions relating to controlling of head and upper body movements could 
be given additionally to the prescribed instructions stipulated in the DEM test 
manual.  If newer tests or modifications for this test are researched, these 
instructions can be recommended to be included to strength the reliability of 
the results. 
 
 Testing of eye movements in paediatric subjects should ideally be done 
objectively limiting the variability, improving reliability and repeatability of 
the results.  For research purposes, visual tracking devices using infrared 
technology can be utilised as instruments of choice for analysing eye 
movements as the sensitivity of these instruments and objectivity is highly 
reliable. 
 
As current research has shown that HIV-associated neurocognitive disorders 
are still persistent in the presence of HAART, children with developing systems are 
still at risk of CNS disease.  In consideration of this, optometrists should take 
cognisance and use this knowledge in clinical practice through specific paediatric 
tests as it would be worthwhile to screen for and monitor neurodevelopmental 









of neurodevelopmental and neuropsychological testing there are an insurmountable 
number of tests that are used in paediatric assessments by various health 
professionals.  The DEM test should be emphasised in this specific population along 
with a battery of other neuropsychological tests that optometrists currently use such 
as the Tests of Visual Analysis Skills (TVAS), Tests of Auditory Analysis Skills 
(TAAS), Tests of Visual Perceptual Skills (TVPS) and the Developmental Tests of 
Visual Motor Integration (Beery VMI). 
 
The role of health care providers should be to actively identify at-risk patients 
to get the appropriate medical attention and rehabilitation that is needed at an earlier 
stage.  This action is critical to prevent children from being handicapped by their 
condition as HIV-associated neurocognitive disorders could be debilitating.  This 
holistic approach to health care could benefit children with HIV/AIDS in levelling 
the playing field to allow them the same opportunities, success and achievement as 
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PATIENT RECORDING FORM  
                                                                             Sample Group            
    
PHASE 1: DEMOGRAPHIC INFORMATION 
 
Assessment Site:                                                          File No.: 
 
Identification Code:     
 
       
        







1st Diagnosed:  
HIV exposure: MTCT   /   other  
 










Viral load:_________        last tested: 
 
CD4 %:_________    last tested: 
 
 
Reason(s) for ARV initiation: _______________________________________ 
______________________________________________________________ 
 
Date of treatment commencement: 
 
ARV med: Duration:  
3TC (Lamivudine) ___ _________ 
d4T (Stavudine)    ___ _________ 
EFV (Efavirenz)    ___                                _________ 
On Tx None 
















PHASE 2: VISION SCREENING INFORMATION 
 





























6. number recognition & fluency:                    9. Pupils: 
  
Numbers: Y  N 
 
7. Refractive error:                                            8. O’scopy: 
 
R:      R: 
 









PHASE 3: DEM TEST RESULTS 
 
 
Developmental Eye Movement Test (DEM) 
 
 



















































Dear Parent/ Guardian/Care-giver 
 
 
re: Research Study for Children that are HIV positive. 
 
This is a request by myself, Mr N. Naicker for your consent for participation in a 
research study of the child in your care.  I am an Optometrist (OP0033847) 
based at National Hospital in Bloemfontein and my study aims to investigate 
eye movements problems in children that are HIV positive.  
 
The information on this sheet would help you understand what is expected of 
the child for you to decide whether you are willing to allow the child to 
participate. 
 
Procedure: Firstly the child would have their vision checked, followed by the 
testing of their eye movements.  Their eye movements would be tested by a 
reading test called the Developmental Eye Movement test (DEM).  This test is 
made up of numbers that need to be read out aloud by the child and their eye 
movements are monitored.   
The time spent with the child will take up to a maximum of 30 minutes in total 
for checking their eyes then getting him or her to read the DEM test.  
 
Confidentiality of the children will be maintained throughout the study and after 
I am completed working with the child.  No names of the children will be used 
in any publication or presentation.   
Instead, each child will be given a code for identification and their names will 
not be used.  
 
As the care giver and welfare responsible for this child, you are under no 











You have the right to not to allow the child to participate and you can withdraw 
from the study at anytime. If you feel so, you may request his or her 
information not to be included in this study.  
 
I hope that you will agree and be willing to allow the child to be a part of this 
study. 
 




Senior Optometrist/Junior Lecturer 
University of the Free State/ Free State Dept. of Health 




































Geagte Ouer / Voog 
Re: informasie oor Navorsings projek 
Ek, Mnr. N. Naicker, wil graag u toestemming vra dat die kind wat in u sorg 
geplaas is mag deelneem aan n navorsings- studie. Ek is n oogkundige 
(OP0033847) wat gebaseer is by die Nasionale Hospitaal in Bloemfontein en 
my studie beoog om die abnormaliteite in oog bewegings in n HIV positiewe 
populasie vas te stel. 
Die informasie op hierdie bylaag sal u help om te verstaan wat verwag sal 
word van die kind en u moet dit eerstens lees voordat u toestemming gee 
daartoe. 
Prosedure: Die kind se visie sal eerstens getoets word en daarna sal die 
oogbewegings ook getoets word. Om te bepaal of daar enige probleme is met 
die oogbewegings, word gebruik gemaak van n toets nl. Die “developmental 
eye Movement test (DEM)”. Elke deelnemer sal instruksies gegee word oor 
wat hy/sy moet doen voordat die toets begin. Die DEM toets bestaan uit n lys 
van nommers wat hardop gelees moet word deur die kind en die 
oogbewegings word dan deur myself gemonitor. Die kind se antwoorde sal 
opgeneem word op band vir my analise. 
Die tyd benodig met elke kind sal op die meeste 30min wees in total. As die 
toets voltooi is, sal geen verdere deelname verlang word nie. 
Vertroulikheid van die identifikasie van die deelnemers sal behou word 
gedurende die studie asook na die voltooing van die studie. Die identifikasie 
van die deelnemers sal ook nie gebruik word in enige publikasie of voordrag 
nie. 
Gedurende die studie, sal n kode aan elke kind toegedien word, sodat geen 
name gebruik sal word nie. As die oog bewegings toets gedoen is by Leboni 
House en dit is die 5de kind wat getoets is wie se naam Jacob Moloi is, sal die 











U het die reg om deelname van die kind te weier en u kan die kind onttrek van 
die studie  enige tyd gedurende die studie. As u so voel, mag u vra dat sy/haar 
resultate nie in die studie ingesluit word nie. 
U is welkom om teenwoordig te wees gedurende die assessering van die kind 
as u sou wou. 






















































DIPATLISO TSA BANA BA NANG LE KOKWANAHLOKO YA HIV 
 
 
Ena ke kopo ya ka Mr Naicker ho wena motswadi/mohlokomedi wa ngwana ho 
nka karolo le ho dumella ngwana ya tlhokomelong ya hao ho kena 
dipatlisisong tsa mahlo.  Ke ngaka ya mahlo (Optometrist) (Mr Naicker-
OP003347) ke sebetsa National H. Mangaung.  Ke etsa dipatlisiso ka mahlo a 
bana ba nang le kokwana ya bosollatlhapi (HIV) 
 
Tse latelang mona di tla o lemohisa hore o utlwisise hore ho lebelletwe eng ho 
wena haeba  o dumella ngwana ho nka karolo dipatlisisong. 
 
 
DITSAMAISO:  Ngwana otla etsa diteko tsa mahlo mahala, ebe ho shejwa 
pono ya hae, motsamao wa mahlo a hae otla lekolwa ka hore a bale se 
bitswang (D.E.M) 
Teko ena e etswa ka di tlhaku tse ballwang hodimo. Morero ke ho sheba kapa 
ho lekola hore mahlo a ngwana a tsamaya ha kae le ho sekamela ka 
lehlakoreng lefe ha a bala. 
Hotla nka metsotso e mashome a mararo he pheta sena. 
Lekunutu ka maemo angwana etlaba ya pele e baballwang le ka morao ho 
moo.  Ha ho mabitso a bana atla sebediswa kapa ho phatlalatswa dipatlisisong 
tsena.  Ngwana otla sebedisa nomoro ya boitsebiso ele ho baballa lebitso la 
hae lannete. 
Jwale ka motswadi/mohlokomedi wa hae ha otlamellwe ho nka karolo empa 
oka enka ha feela o dumela. 
Onale tokelo ya ho hanela ngwana wa hao ho nka karolo dipatlisisong tsena 
















Senior Optometrist/Junior Lecturer 
University of the Free State/ Free State Dept. of Health 



















































I, ………………………………………………………., am the parent/ legal 
guardian/ care giver of ……………………………............................and I hereby 
give permission for child above to participate in this research study. I have read 
the information provided to me on the information sheet. I fully understand my 


































Ek, …………………………………………………………………., is die ouer / 
wettige voog / versorger van …………………………………………………en 
hiermee gee ek toestemming vir die bogenoemde kind om deel te neem aan 
hierdie navorsings-projek. Ek het die informasie aan my voorsien  gelees. Ek 
verstaan ten volle my regte en wat verwag sal word van die kind en is 


















































wa.......................................................................................ke fana ka tumellano 
hokenya ngwana waka Dipatlisisong tsena.  Ke badile le ho utlwasisa dikateng tsohle 











_______________________    __________________ 
Signature       Date 
Appendix C3 
